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ABSTRACT
Investigations of CHO-1-15 and Silk Gland Cell Line Development
by
Susan K. Robinson, Master of Science
Utah State University, 2014
Major Professor: Dr. Jon Takemoto
Department: Biology
The BioProcessing Demonstration and Training Laboratory was established with
a collaboration between Utah State University and Thermo Fisher- Scientific, Inc. and
developed into an operational tissue culture facility. Demonstration and establishment of
tissue culture protocols were necessary to be industry-fully qualified. The CHO 1-15 cell
line protocols were optimized by establishing conditions for reproducible growth curve
profiles in shaker flasks and bioreactors (2 to 250 L capacity). CHO 1-15 is the cell line
of choice for protein production in the bio-manufacturing industry. Oxidative stress is
problematic in industry because it causes a decrease in protein production.
Mesobiliverdin IXα and biliverdin IXα possess similar antioxidant properties. The effects
of the antioxidant nature of these compounds were investigated on the CHO 1-15 cell
line. Cultures from silkworm and spider silk producing cells were also pursued. Methods
to produce a primary cell line from spider silk gland cells were developed. Cell lines from
spider and silkworm silk producing glands appeared to have the capacity to secrete fulllength native proteins ranging in size from 200 to 500 kDa, and possibly larger.
(132 pages)
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PUBLIC ABSTRACT
Investigations of CHO-1-15 and Silk Gland Cell Line Development
Susan K. Robinson
The BioProcessing Demonstration and Training Laboratory was
established with a collaboration between Utah State University and Thermo FisherScientific, Inc. This lab was developed into a fully functioning tissue culture facility.
Demonstration of tissue culture procedures were necessary for the lab to be industry-fully
qualified. The CHO 1-15 cell line protocols were optimized by establishing conditions
for reproducibility in shaker flasks and bioreactors (2 to 250 L capacity). CHO 1-15 is the
cell line of choice for protein production in the bio-manufacturing industry. Oxidative
stress is a problem in the industry because it can cause a decrease in protein production.
Mesobiliverdin IXα and biliverdin IXα possess antioxidant capabilities. The effects of
the antioxidant nature of these compounds were tested on the CHO 1-15 cell line. Cell
cultures from silkworm and spider silk producing cells were also pursued. Methods to
produce a primary cell line from spider silk gland cells were developed. Cell lines from
spider and silkworm silk producing glands appeared to have the capacity to secrete fulllength native proteins ranging in size from 200 to 500 kDa, and possibly larger.
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CHAPTER 1
INTRODUCTION

PART 1: CHO 1-15 GROWTH STUDIES
The Chinese hamster (Cricetulus griseus) belongs to a rodent family that is native
to the deserts of Northern China and Mongolia (1). This species was first catalogued in
1773 (2). Since 1919, the Chinese hamster has been used in biomedical research and is
presently credited with saving many lives from a variety of illnesses, including cancer,
each year (1). In the mid-20th century the hamsters were mainly used in epidemiological
research. That changed in 1957 when Theodore Puck from the University of Colorado
took cells isolated from an ovary of a Chinese hamster and was able to establish them in
culture plates (1). That isolation later became known as the CHO (Chinese Hamster
Ovarian) cell line.
CHO cells have been termed the mammalian equivalent to the model bacterium,
Escherichia coli, because of their frequent use in biological studies (1). There are several
mutant strains of CHO cells because they are highly resilient, are easily manipulated, and
are capable of foreign gene amplification (1) (3), which makes CHO cells the mammalian
expression system of choice for bio-manufacturers (2). For the past 20 years, CHO cells
have been a major bio-manufacturing platform for protein pharmaceuticals including
anticancer therapeutics, hormone treatments, and the widely used anti-blood clotting
drug, human tissue plasminogen activator (tPA) (1). It has also been established during
the past 20 years that CHO cells do not allow for the propagation of many pathogens that
affect humans, making these cells a safe host for therapeutic protein production (1). CHO
cells are not the expression system of choice just because they are safe hosts, but also
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because they are adaptable and can be genetically manipulated with ease (1). CHO cells
can be adapted for growth in serum free conditions. This adaptation allows for the cells to
be scaled up to high densities in suspension using large scale bioreactors (10,000 L plus).
Increased cell density makes it possible for increased quantity of product (1) (3).
Bioreactors provide a low stress environment by controlling agitation and aeration in
large tanks. The use of bioreactors to grow industrial cell lines makes it possible to
culture high volumes of mammalian cells, which will lead to the increased production of
proteins (4).
In 1986, the FDA approved the first therapeutic protein, tPA, from recombinant
mammalian (CHO) cells (3). The use of CHO cells to secrete tPA triggered the
development of mammalian cell culture for biopharmaceutical production (3). Seventy
percent of all recombinant therapeutic proteins produced today are made in CHO cells
(3). The market value for cell-produced protein therapeutics is in excess of $112 billion
and is expected to grow to $143 billion by the end of 2015 (information available at
http://www.rncos.com/Report/IM389.htm). Since CHO cells are the major platform for
recombinant therapeutics production, the optimization and study of their growth and
maintenance is critical to maximize protein production and, therefore, maximize profits.
Mammalian cells proliferate in culture with a standard growth pattern. The first
phase (lag phase) of growth is a time in which cells grow slowly because they are
adapting to the culture. The next phase, the log phase, is the most important phase for
reaching maximum cell densities and maximum protein production because cells are
proliferating exponentially. Growth medium and nutrients are critical during the log
phase. When the medium is spent, the cells enter a stationary phase where proliferation

3
ceases. At this point, the cells can no longer live and enter the death phase. Figure 1-1
shows the characteristic growth pattern of cultured cells. The semi-logarithmic plot
shows the cell density versus the time spent in culture (information available at
http://www.invitrogen.com/cellculturebasics).

Figure 1-1: Cell growth phases (information available at
http://www.invitrogen.com/cellculturebasics).
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Table 1-1 lists several different techniques for improving cell culture for the biomanufacturing industry. Developing and optimizing new media is a method that will
maximize protein production during the log phase of growth with various mutant strains
of CHO cells. Thermo Fisher Scientific, Inc. (TFS) developed a HyCell CHO medium
that is formulated specifically for CHO cell lines grown in suspension. The HyCell
medium is a serum free, chemically-defined medium that was formulated using
Metabolic Pathway Design (HyCell CHO information available at
http://www.gelifesciences.com). This medium is just one example of the many types of
media that have been developed by bio-manufacturing companies to provide higher cell
densities to increase product yield and quality (HyCell CHO information available at
http://www.gelifesciences.com).

Table 1-1: Techniques for improving cell culture on the large scale (4).

Cell line development
Metabolic fingerprinting of
cell line
Medium optimization
Process optimization
Bioreactor optimization
Growing use of
disposables

Stable or transient high producing cell
lines
Glucose, amino acids, NH₄ , lactate,
osmolarity, etc.
Serum-free, protein-free, chemically
defined media
Cultivation parameters process mode
Heat transfer, shear forces, mixing
pattern, residence time distribution,
oxygen transfer efficiency
Single-use bags for medium storage,
sampling, seed inoculum, disposable
couplers, sensors and bioreactors
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In 2012 the BioProcessing Demonstration and Training Lab located in the
Innovations Campus Building 650 was established. The Lab is the result of a successful
collaboration between Utah State University (USU) and TFS. The lab is a full functioning
tissue culture and bioprocessing lab with state-of the-art equipment. Experiments
performed in the BioProcessing Demonstration and Training Lab fulfill contractual
agreements with TFS. The tPA secreting CHO 1-15 cell line is grown in the Formulated
HyCell CHO medium. The CHO 1-15 cell line (1) was obtained from the ATCC and then
adapted to propagate for growth in suspension by TFS. Experiments demonstrating
mammalian cell growth curves and protein production are necessary for developing and
optimizing tissue culture and bioprocessing protocols. The adapted CHO 1-15 cell line
will initially be used for growth studies ranging from small-scale shaker flask growth
studies all the way to large scale bioprocessing platforms.
The three main objectives that must be completed for the Thermo Fisher
collaboration, which are focused on protein quantity and production, are as follows:
1. Characterization of cell count and viability of CHO 1-15 cells grown in
suspension.
2. Quantification of tPA produced by CHO 1-15 cells.
3. Upscale platforms: shaker flask, bench top bioreactor 2L, single use bioreactor
(S.U.B.): 50L, 100L, and 250L.
The S.U.B. bioprocess containers provide for an environment that is optimal for
protein production by CHO cells by allowing parameters such as oxygen, pH,
temperature and agitation to be controlled. Also, the S.U.B. tank supports a bioprocessing
bag (BPC) which comes pre-sterilized and ready to use. This provides a safe and sterile
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environment for the cells to grow. The main goals in CHO cell protein production are to
obtain higher protein quantity and quality. High growth yields and optimized growth
conditions are best achieved in controlled bioreactors. This project focuses on using
optimized conditions (S.U.B., media) to evaluate the growth conditions of CHO 1-15
cells grown in suspension. A controlled environment and specialized HyCell CHO media
allow the cells to grow better and produce high yields of tPA.

PART 2: HEME-DERIVED ANTIOXIDANT COMPOUNDS
Oxygen is necessary for biological function; unfortunately, the events that utilize
oxygen come with the byproduct, reactive oxygen species (ROS) (5). The ROS include
free radicals such as the superoxide anion (O₂ˉ), the hydroxyl radical (∙HO), and the nonradical hydrogen peroxide (6). The cell has natural anti-oxidant defenses which are superoxide dismutase (SOD), catalase, and glutathione (GSH). The cell can become
overwhelmed when the concentration of ROS is too high for its antioxidant capabilities.
In response to this stress, the cell will begin to down-regulate normal protein production
and put efforts into producing antioxidant defenses, such as the heat shock proteins (7).
The depletion of antioxidant defenses can result in oxidative damages within the cell. At
the same time the normal cell cycle will be suspended in an effort to focus resources on
cell survival. If the damages are severe enough it will cause cell death by apoptosis or
necrosis. Oxidative stress can be observed when eukaryotic cells or tissues are exposed to
agents such as peroxides, glutathione-depriving drugs, toxins, radiation, and
inflammatory cytokines (5). It is important to note that oxidative stress in cells has been
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shown to have pathological implications in humans such as promotion of Alzheimer’s
and Parkinson’s diseases, cancer, and aging (7).
Other factors that can trigger oxidative stress in cells are oxidation, heat, toxic
contamination, and physical stress. Once oxidative stress is triggered in a cell, there is a
down-regulation of normal gene production. This happens to conserve cellular energy for
use in neutralizing the damage. Low concentrations of hydrogen peroxide have been
shown to lead to an arrest in cell growth and a lengthening of the cell cycle (7).
Biliverdin IXα (BV IXα) is a green bile pigment and is involved in the catabolism
of heme (information obtained from http://en.wikipedia.org/wiki/Biliverdin). The
oxidation of heme leads to BV IXα (8). BV IXα is further reduced to bilirubin. It is
believed that the reduction of BV IXα to bilirubin is very rapid (8). Both BV IXα and
bilirubin are water-insoluble pigments that possess antioxidant properties (9). In the late
1980s, it was demonstrated that the antioxidant effect of bilirubin exceeds that of vitamin
E toward lipid peroxidation (10). It is thought that BV IXα participates with bilirubin in
an oxidation/reduction cycle. Shown in Figure 1-2 is bilirubin acting as an antioxidant,
oxidized to BV IXα and then recycled by biliverdin reductase back to bilirubin (11). BV
IXα exists in trace amounts in vivo during heme metabolism (8). During one study, only
small amounts of bilirubin (10 nM) were needed to protect neuronal cells from a 10,000
fold molar excess of H₂O₂ (8).
Mesobiliverdin IXα (mesoBV IXα) is a close analog of BV IXα (12). MesoBV
IXα is produced from phycocyanobilin. The chromophore phycocyanobilin is recovered
from lyophilized powders of the cyanobacteria Spirulina platensis (12). MesoBV IXα has
demonstrated anti-oxidant capabilities (12). When mesoBV IXα was used to protect
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pancreatic islet cells from oxidative stress, a very low concentration (1 µM) of mesoBV
IXα was needed (12). That cytoprotective capability was better than the commercial BV
IXα (12).

Figure 1-2: Oxidation and reduction cycle of BV IXα and bilirubin (10).
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Phycocyanin is also proven to be a strong antioxidant (13). The chromophore of
phycocyanin is phycocyanobilin (PCB). PCB is similar to the chemical structure of
bilirubin and is also a scavenger of ROS (13). The structure of PCB is similar to that of
BV IXα and it appears to be susceptible to biliverdin reductase, which results in
phycocyanorubin, an analog of bilirubin (14). Phycocyanin and PCB are isolated from S.
platensis (14). PCB is important in the antioxidant properties of phycocyanin because it
contains antioxidant and radical scavenging abilities (14) (15).

Figure 1-3: Structures of heme-derived compounds: BV IXα, mesoBV IXα and PCB.
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CHO cells are the main bio-manufacturing biological system for protein
pharmaceuticals including anticancer therapeutics, hormone treatments, and the antiblood clotting drug, tPA. The market value for cell produced protein therapeutics is in
excess of $112 billion and is expected to grow in the future (information available at
http://www.rncos.com/Report/IM389.htm). As of 2009, few studies on oxidative stress
had been performed on mammalian eukaryotic cells, despite the fact that mammalian
cells are often used to produce high cost, recombinant human protein products (such as
tPA) (7). CHO cells are used to produce these complex proteins because they require
certain modifications to be functional and prokaryotic cells cannot make those
modifications (7). There is a lack of knowledge about how CHO cells react to oxidative
stress when used for large-scale platforms even though oxidative stress is a huge concern
and is problematic in the industry of mammalian cell growth because it causes downregulation of protein production, slower growth, and decreased viability (7).
Menadione and hydrogen peroxide are two chemicals that have shown to cause
oxidative stress and be toxic in CHO cells. Menadione (2-methyl-1, 4-naphthoquinone)
is a redox cycling quinone (7). Menadione is an artificial form of Vitamin K3 and an
oxidant that raises O₂ˉ concentrations (7). That in turn forms ROS (5). The ROS then
induces a rapid oxidation of antioxidant defenses, including glutathione (GSH) (5). With
concentrations ranging from 50 μM to 750 μM, menadione was found to induce oxidative
stress in human skin fibroblasts after 30 min of exposure (7) (16). Menadione has not
been used on CHO 1-15 cells but on a different strain of CHO cells and has worked as a
strong oxidant with a rapid effect causing the majority of cells to die after 1 h of exposure
(7).
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Hydrogen peroxide (H2O2) is a stable compound and a regularly used oxidant that
can pass freely through membranes and raise the intracellular level of peroxides. H2O2
participates in the catalytic fenton reaction (7). It is changed to a hydroxyl radical, a short
lived but very potent ROS that oxidizes macromolecules inside the cell (5). The hydroxyl
radicals will cause rapid oxidation of reduced GSH (5). The cell type and media
composition determines the necessary concentration of hydrogen peroxide needed for
oxidative stress induction. When H₂O₂ is added directly to the culture medium, the cells
will experience a short-term exposure to a quickly decreasing concentration of H₂O₂
(17). The cell population density plays an important role in the rate at which the H₂O₂
diminishes (17). At high densities cells are less susceptible to the cytotoxic effects of
H2O2; this is due to the fact that H₂O₂ will be detoxified when the cell activates its own
antioxidant defenses (18). It is thought that glutathione peroxidase acts as the
predominant defense enzyme against lower H₂O₂ concentrations (17).
The use of the three heme-derived compounds BV IXα, mesoBV IXα, and PCB
on CHO cells could have the potential to increase protein production and quality. Due to
the nature of the antioxidant properties of each compound and their similarities to each
other in structure, it would be expected that all three would yield similar results when
tested on a CHO cell line. The billion dollar protein therapeutics industry is constantly
researching ways to maximize protein production with CHO cells, and finding
compounds that minimize oxidative stress could have a significant impact.
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PART 3: SILK GLAND CELLS
Around 4,500 years ago, an empress of China dropped a silkworm cocoon into a
cup of tea. The cocoon unraveled and, with that, the empress wove the first thread of silk
(19). This discovery is believed to have started the use of silks for the benefit of human
societies (19). For thousands of years, silk from the silkworm, Bombyx mori, has been
used to produce fabrics. Commercial use of this silk from B. mori has been developed for
centuries. The silkworm is not the only animal that produces silk in nature; scorpions,
mites, flies, and spiders are all examples of insects that produce silk (20). Currently, there
are around 37,000 known species of spiders which all produce some kind of silk, and
about half of those produce silk to spin webs (21).
The spider began its evolutionary process of using silk about 400 million years
ago (22). For thousands of years, societies have been using spider silk for their benefit,
two examples being fishing lines and webs to stop bleeding from wounds (23). Despite
the fact that spider silk benefits have been known for centuries, spider silk has only begun
to be extensively studied in the last few decades. One reason spider silk has not been
studied is because farming spiders for large-scale silk production is not possible because
of their highly territorial and cannibalistic nature (24).
The study and use of spider silk has great potential to make new, improved
products. Spider silk is much tougher than the brittle cocoon silk of the silk worm (22).
The tensile strength of spider silk is comparable to steel and the elasticity to that of
rubber (25). Due to those properties, the toughness of the silk is two or three times higher
than Kevlar (25). Other properties of silk that make it useful, especially for biomedical
products, are that it is antimicrobial, hypoallergenic, and biodegradable (25).
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Orb-weaving spiders live off of the ground and use a web to catch their prey (26).
The name of these spiders comes from the orb shape of the web they produce. The orbweavers have six different silk producing glands and one glue producing gland (26), see
Figure 1-4 below. All of these glands produce a silk that is necessary for the spider’s
survival. Some of the functions include locomotion, prey swathing, web construction, and
egg protection (21). Those different functions give the silk unique mechanical properties,
which make these spiders and their different silks especially desirable to research.
Silk proteins (spidroins) produced by the six different silk producing glands
generally have relatively high molecular weights of 200 to over 350 K (27). The
synthesis of these spidroins occurs in columnar epithelial cells (26). The newly formed
proteins appear as droplets in the cell that are exocytosed into the lumen of the gland
where they can be stored until needed by the spider (26) (28). The “droplets” are thought
to form a micelle structure in the lumen of the gland. Changes in the pH along with shear
forces (from the spider moving its abdomen or pulling with its legs) cause a mechanical
change, thus linearizing the micelle structure and allowing it to re-fold into fiber
formation as the proteins travel into the duct of the gland, forming the spider silk fiber
(25) (27). This method of action for silk fiber formation is thought to be the same for all
of the silk producing glands.
The major ampullate glands are the most studied of all the silk producing glands,
partly due to their large size (26), as a result most of the information available on spider
silk is from the silk produced by the major ampullate glands. Two proteins make up the
silk produced from the major ampullate glands: Major ampullate spidroin 1 (MaSp1) and
Major ampullate spidroin 2 (MaSp2). These proteins are extremely large, with molecular
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weights between 275 K and 320 K (22). The major ampullate glands produce silk that is
used for the structural frame lines of webs and for dragline silk (the spiders’ life-line,
should they fall) (25) (26). The dragline silk, made up of the two MaSp proteins, is
extremely tough and has a tensile strength comparable to Kevlar (24).

Figure 1-4: Spider silk glands and their products (29).
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The silk from the minor ampullate glands is used for the auxiliary spiral silk
construct (25), and is used as the structural reinforcement in the web. The minor
ampullate glands produce at least two proteins: Minor Ampullate Spidroin 1 (MiSp1) and
Minor Ampullate Spidroin 2 (MiSp2) (26). The molecular weights of these proteins are
also very large, around 250 K (26). The MiSp2 protein is similar to the major ampullate
silk and is often spun at the same time (30). One major difference between major
ampullate silk and minor ampullate silk is that minor silk does not have the elasticity that
the major silk has, one reason being that minor silk has virtually no proline (26) (30).
The aciniform gland produces a silk that is used for wrapping the prey silk and the
inner egg case (31). The main protein stored in the numerous aciniform glands is AcSp1
(26). The mechanical properties of aciniform silk are quite different than the silk
produced from the other glands. The main difference is the toughness of the fiber
compared to the other silks. This includes the overall strength, stiffness, and elasticity of
the fiber (32).
The piriform gland secretes the attachment cement silk for the web (25). There is
only one known piriform spidroin, PySp1 (28), but it is thought that the silk from the
piriform gland is comprised of more than one protein (33). This gland produces accessory
proteins, which are also considered to be glue proteins.
Flagelliform glands secrete the capture spiral silk. The silk made by the
flagelliform glands is a tremendous component of elastic support for the capture of prey
in the orb-web (22) and is dotted with the glue-like silk from the aggregate gland (34). It
is the extensibility feature of this silk, combined with the tensile strength, that make it
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one of the hardest silks to break (34). The gland is thought to secrete one extremely large
spidroin (Flag) 500 kDa in size (26).
Tubuliform glands are unique among orb-weavers (26). The silk is known as egg
case silk and is only produced during the reproductive season (35) from sexually mature
females. There has been one protein identified, secreted by the glands, as TuSp1 (26).
The silk is very similar to minor ampullate silk because it has high strength but low
elasticity (36), although it is brittle and the amino acid sequence is very different.
The glue producing aggregate glands help the spiders with many tasks: web
construction, prey capture, and locomotion (31). Not much is known about the glue
proteins, but there are two specific known proteins from the aggregate gland: AgSf1 and
AgSf2, which are around 40 to 60 kDa (31).
Nephila clavipes is known as the golden orb weaver (26) because it is an orb-web
spinning spider with golden silk (37). These spiders are one of the most studied spiders
(24) because they make good lab animals and are large in size. The dragline silk from the
major ampullate glands of the N. clavipes was the first spider silk to ever be studied (37).
Attempts have been made with several different expression systems for the
synthetic production of spider silk (38), all with pros and cons. A common disadvantage
that these different expression systems have is that none can produce native full-length
synthetic spider silk proteins, whether on a small scale or a large-scale basis. A reliable
system for the large-scale production of spider silk is necessary if spider silk is going to
be used at a commercial level. Figure 1-5 is a summary of the attempts at recombinant
spider silk production.
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Table 1-2: Spider silk function (25).
Gland

Function

Major Ampullate Silk Gland Structural and dragline silk
Minor Ampullate Silk Gland Auxillary spiral thread
Flagelliform Silk Gland

Capture spiral thread

Piriform Silk Gland

Attachment cement

Tubuliform Silk Gland

Tough outer egg case

Aciniform Silk Gland

Soft inner egg and wrapping

An expression system in the bacteria E. coli has been developed. This system has
been good for large-scale production via fermentation. Maintenance cost of bacterial
cultures is comparatively low. Unfortunately, spider silk production in bacteria results in
unstable DNA fragments, low protein yields, and solubility problems. Also, endotoxins
must be removed before use in biomedical applications (38). Yeast cells can perform
post-translational modifications and produce high yields; however, modifications in yeast
can be different than the more evolved eukaryotic cells. Also, undesirable glycosylations
can be present, which increase the chances of an allergic reaction when the silk is used
for biomedical purposes (38). When the expression system is a plant, there can be toxic
substances in plant vacuoles, and plant antigens can cause allergic reactions which would
be a problem when using silk produced from plants for biomedical purposes (38). There
have also been attempts to produce silk in mammalian cells. Hamster, bovine, and goat
mammary cells have been used, but contamination and complex media might be a
problems (38) (39). Transgenic animals have also been used, one example being goats.
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The spider silk proteins MaSp1 and MaSp2 are excreted from the mammary glands into
the milk of the goat, but the yields are low and the development time is long, (38)
because the milk is only produced for a few months out of the year.

Figure 1-5: Spider silk expression systems (40).
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A continuous insect cell line was first established in 1962 when Thomas Grace
was able to grow female moth ovaries from the Antherea eucalypti (41). Since the year
2000, over 500 insect cell lines have been established. Around 80% of those came from
Lepidoptera and Diptera, with only 20% from all other invertebrates and only 5% of
those being from non-insect (42). Around half of the insect cell lines have come from
embryonic tissue and, as a result, have mixed morphologies. That can be an issue when
the desire is to answer a specific tissue function question.
Insect cell culture success is dependent upon antibiotics, improved medium, and
patience (41). The small size of the animals and the “dirty environment” they live in
make it difficult for a successful culture (41). Fortunately, there has been some success
despite the obstacles. For example, cultures with the “dirty” house fly and with a very
small wasp have been achieved (41). These successes were achieved largely due to the
advances and development of antibiotics and the use of growth supplements in the media.
The methods for establishing primary (finite) and secondary (continuous) insect cell lines
are still poorly developed (43). The use of transformation, the process of immortalizing a
cell line or transforming it from a primary cell line to a secondary cell line, are well
studied within mammalian cells (43). The chemical, N-methyl-N′-nitro-Nnitrosoguanidine (MNNG), a mono-functional alkylating agent that causes chromosomal
DNA damage, has been used as a chemical transformation means for immortalizing
mammalian cells and has been used successfully for transforming insect cells from a
primary to a secondary culture (43). Unfortunately, MNNG is illegal in the U.S., but a
similar mutagen N-Nitroso N-methylurea (MNU) has been recommended by Sigma
Aldrich and is available for use in the U.S.
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There are no published successful attempts at developing a cell line from the
glandular epithelial spider silk producing cells. There are multiple reasons for the need of
a spider silk producing cell line. One reason being that it would benefit and further the
research and understanding of the spider silk production itself. These cells not only could
be a means of spider silk production, but they may also answer questions like, do
different cell types secrete the different spider silk proteins or is it one cell type per
gland? A cell line from one of the spider silk producing glands should have the capacity
to secrete full-length native proteins, which could range in size from 200 kDa to 500 kDa,
possibly larger. Also this cell line could be used to further insect cell recombinant
technologies production. It has already been demonstrated that insect cell lines are good
choices for expression of recombinant molecules, including antibodies (44). In some
cases expression levels with insects are higher than with mammalian cells (44). Also
insect cells have the capability of post-translational modifications that would be
provided by a eukaryotic cell (44). Antibodies are fairly large proteins, and a cell line that
is made primarily to secrete very large proteins could be extremely beneficial to the
multi-billion dollar industry of recombinant therapeutics (45) that is expected to have a
surge of growth in the next 10-20 yr (46). For example, a cell line developed from the N.
clavipes major ampullate glands should be ready-made cell factories that are already
programmed to secrete very large spidroins ~350kD. That gene could be spliced out and
a protein of interest inserted, and the cell should have all the capabilities to produce that
protein. Most of what is known about silk is from dragline silk which comes from the
major ampullate (26). An immortalized cell line available that can secrete full-length
spidroin proteins could be the solution for the large-scale production of spider silk.
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SUMMARY OF RESEARCH OBJECTIVES
The research contained in this thesis is devoted to the growth, maintenance and
optimization of cells adept at producing protein in high yield and of optimal quality. Cells
expressing proteins of interest are isolated, maintained, quality assured, and supplied to
meet the objectives. The following are those main objectives:
1. Establish operational qualification bioreactor runs for Thermo Fisher
Scientific Inc.:
a. Quantify the cell number and viability of CHO 1-15 cells grown in
HyCell CHO media from shaker flasks to bench top bioreactor (2 L)
and single use bioreactors (50L).
b. Quantify human tissue plasminogen activator (tPA) produced by CHO
1-15 cells.
c. Adapt protocols and establish for use in BioProcessing Demonstration
and Training Lab (Appendices A, B, C, D, E, F, G and H).
2. Determine the antioxidant capability of heme-derived compounds (mesoBV
IXα, BV IXα, and PCB), by using CHO 1-15 cells and measuring cell growth
and viability via the trypan blue exclusion dye method.
3. Establish a silk gland cell line into primary culture.
a. Establish protocols for silk gland isolation for primary cultures by
optimizing medium and methods.
b. Test the MNU compound for immortalizing primary cell cultures.
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CHAPTER 2
CHO 1-15 GROWTH STUDIES
More than two thirds of the recombinant therapeutic proteins of the biotechnology
industry are produced using the CHO cell line. The main goals in CHO cell protein
production are higher protein quantity and quality. The ongoing efforts for the growth and
maintenance of the mammalian cell line CHO 1-15 was assessed and characterized in the
BioProcessing Demonstration and Training Lab. This lab was a result of collaborative
efforts with Thermo-Fisher Scientific (TFS). The research on the CHO 1-15 has been
used to establish in-house protocols, growth curves, and tissue plasminogen activator
(tPA) production patterns. The growth studies presented in this chapter start with a shaker
flask and are scaled up to a 50 L single use bioreactor (S.U.B.).
The growth study experiments for the TFS collaboration are completed with the
CHO 1-15 cell line grown in HyCell CHO media, a specially formulated animal derived component free media from TFS designed to maximize recombinant protein production
from CHO cells. The growth study objectives are:
1. Quantify the cell number and viability of CHO 1-15 cells grown in suspension.
2. Quantify human tissue plasminogen activator (tPA) produced by CHO 1-15
cells.
3. Increase growth platform scales from shaker flasks to a bench top bioreactor (2 L)
and single use bioreactors (S.U.B.s) (50L and 250 L).
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MATERIALS AND METHODS
The CHO 1-15 cell line was obtained from TFS, which adapted the cell line for
growth in suspension using selection. The CHO 1-15 cells were brought out of
cryopreservation storage and scaled up for growth following the protocols in Appendix A
and B. A working stock of CHO 1-15 cells were cryopreserved following Appendix C.
The CHO 1-15 cells were grown in suspension at 37 °C, 95% humidity, 5% CO2 at 125
RPM . The HyCell CHO media was obtained from TFS in powder form and prepared
following the protocol in Appendix D.
The total viable cell concentration and the percent viability were determined using
the trypan blue exclusion method via the Vi-CELL Cell Viability Analyzer from
Beckman Coulter. Trypan blue is a molecule (FW: 960.8) that can only penetrate cells
that have damaged membranes (5). This principle allows the percentage of the stained
(dead) cells in relation to the unstained (alive) cells to be calculated (Figure 2-1). The ViCELL takes 50 images of a 0.5 mL to 2.5 mL sample. The Vi-CELL averages the 50
images, yielding the % viability and the total viable cell count via the stained cells and
unstained cells. The cell counter also has other data available including the average
diameter and circularity of the cells (Figure 2-1). The Vi-CELL protocol found in
Appendix E is used when collecting samples for viability and concentration.
Under healthy growth conditions the CHO 1-15 cells secrete tissue plasminogen
activator (tPA) into the media. One mL cell samples were collected for the tPA ELISA
and centrifuged at 1,000 RPM for 4 min. Samples are stored at -20°C until it is time to
perform an ELISA. The concentration of recombinant tPA (in the supernatant) is
analyzed using the kinetic sandwich ELISA method (www.enzymeresearch.com) and the
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SpectraMax spectrophotometer. The ELISA kit was purchased from Enzyme Research
Laboratories and comes with the capture antibody and the detecting antibody. The
standard was purchased from Calbiochem (cat #612200) for 100 µg of human tPA. The
standard was re-suspended in sample diluent to a final concentration of 10 µg/mL. The
ELISA protocol in Appendix F was used for the analysis. The CHO 1-15 cells secrete 22
mg per L when grown in a standard CHO media (CD-CHO Invitrogen) (47). That value,
21.9 mg, will be used as a reference value for the tPA produced in the following
experiments.

Figure 2-1: Image of CHO 1-15 cells from the Vi-CELL counter along with the data that
is available when used.
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Shaker Flask Platform. The shaker flask growth study was started using CHO 115 cells that had been in culture for at least 1 month. Each study was run in triplicate.
After performing a cell count (Appendix E), the three PETG Erlenmeyer 250 flasks were
seeded to a final volume of 100 mL. The target density for all shaker growth studies on
day 0, or “start seed” was 250,000 cells/mL. Cells were grown in sterile filtered HyCell
CHO media (TFS) on MAXQ 2000 platform shakers (TFS) at 125 RPM, incubated at
37°C, and 5% CO₂ in a Reach in CO₂ incubator (3950) from TFS.
Two 1 mL samples were collected on days: 3, 5, 7, 10, and 12 for the Vi-CELL
Analyzer and for tPA quantification. The 1 mL sample collected for tPA determination
was centrifuged at 1,000 RPM for 4 min. The supernatant was collected and stored at
-20°C until analysis with the tPA ELISA protocol could be completed (Appendix F).
Bioreactor Platform (2 L). The 2 L bioreactor growth study was conducted with
the APPLIKON Bio Console ADI 1025 bioreactor control unit and a 2 L glass vessel.
The temperature was controlled with a heating jacket and maintained at 37°C. The pH
was set at 7 and maintained using CO₂ through gentle sparging and the addition of
sodium carbonate monohydrate. The dissolved oxygen (DO) was maintained at 50% of
air saturation by gentle sparging of air and O₂. The CHO 1-15 cells used for the
experiments were kept in culture 1-3 months. The 2 L bioreactor setup and maintenance
protocol is found in Appendix G. Each bioreactor study was seeded from a PETG
Erlenmeyer flask of CHO 1-15 cells in logarithmic growth phase. Logarithmic growth
phase was determined from the shaker growth studies which was between day 3 and 6 of
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growth. The target seed density for all three runs was 250,000 cells/mL, which was
determined using the Vi-CELL protocol (Appendix E).
A 1 mL sample was analyzed on the Vi-CELL each day of the study, starting at
day 0 and continuing through day 11. Samples were collected around the same time of
day for consistency. The sample was centrifuged at 1,000 RPM for 4 min. The
supernatant was collected in a new microfuge tube to be used for tPA quantification. The
tPA sample was analyzed with ELISA (Appendix F). A 1 mL sample was collected for
the bioprofile analysis using the BioFLEX instrument. The analysis was done by TFS
using an in house protocol.
S.U.B. Bioreactor Platform (50 L). Large scale bioreactors are mainly used to
produce mass quantities of recombinant proteins. These reactors can provide for an
environment that is optimal for protein production. The main goal in using large scale
bioreactors to grow CHO 1-15 cells would be to yield higher protein quantity and quality.
The 50 L S.U.B. bioreactor growth study was conducted with the Pendotech bioreactor
control system (PCS-BRBA) and a 50 L S.U.B. with the appropriate size of
bioprocessing container bag (BPC). The control unit, the S.U.B., and the BPC bags were
provided by TFS as part of USU’s collaboration with them. The S.U.B. bioreactor along
with the supporting BPC bags are a new technology designed for large scale
bioprocessing. The S.U.B.’s have been developed by TFS to reduce the risk of
contamination and cross-contamination, reduce cleaning time, and allows for process
success and flexibility. The BPC bags come completely sterilized and ready for use. The
BPC bag fits inside the supporting 50 L S.U.B. tank. The bag is designed around the
conventional stirred tank bioreactor and comes with ports that are provided for liquid
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transfer, gas control, monitoring, and sampling. The ports make it easier to maintain
sterility in the system. The protocol for loading the BPC bag into the 50 L S.U.B. tank is
found in Appendix H.
CHO 1-15 cells were used that had been growing in culture for 1-3 months. The 2
L bioreactor was used to prepare a seed culture for the 50 L S.U.B. in order to ensure
enough cells for the target cell seeding density (250,000 cells/mL) was achieved. When
the 50 L bioreactor was seeded the cells used were in logarithmic growth phase to ensure
that the cells would continue to grow normally and were not under stress. The protocols
used to upscale the CHO 1-15 cell line and the 2 L bioreactor are found in the
Appendices B and G. The BPC should be filled with media one day prior to seeding
because the electric heating system took 4-6 h to get 50 L of media up to 37°C. The
protocol for filling the S.U.B. with media is found in Appendix H. While the bioreactor
was filling with media, the pH probe was calibrated according to the user manual. The
pH and the DO probes had to be autoclaved in the Kleenpak connector ports to maintain
sterility. Once the bioreactor was filled with media, the system was warmed to 37°C. The
sterile probes were then inserted into the appropriate ports with aseptic technique and per
user guide instructions. The DO probe was allowed to polarize in the warmed media
overnight (minimum of 6 h). Table 2-1 lists the parameters and set point values for the 50
L bioreactor.

Table 2-1: The parameters and set point values for the 2 L and 50 L bioreactor.
Parameters

DO

pH

Temperature

Agitation

Anti‐foam C

Set Points 2L
Set Points 50L

50%
50%

7.0
7.0

37°C
37°C

300 RPM
180 RPM

13 mL
350 mL
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The next morning the DO probe was calibrated. The protocol found in Appendix
H was used for seeding the 50 L S.U.B. The target starting density for the two 50 L
bioreactor runs was 250,000 cells/mL. The advantage of using bioreactors is being able to
control parameters that affect protein production from cells. This kind of control is not
available with flasks and incubators. The set point values for the 2 L and 50 L bioreactor
are found in Table 2-1. The temperature was controlled with an electric heating system
and was maintained at 37°C. The pH was set at 7 and maintained using CO₂ through
sparging at the base of the bioreactor and the addition of sodium carbonate monohydrate.
The dissolved oxygen (DO) was maintained at 50% air saturation by the use of macro
and micro sparging of air and O₂. Figure 2-2 shows the maintenance capability that the
Pendotech controller system performed with the pH and DO value set points during run
1.

Figure 2-2: The pH and % dissolved oxygen maintenance by the pendotech controller
during run 1.
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During the course of a S.U.B. run, the most probable chance of contamination is
during sampling. By using sterile technique, the risk of contamination while sampling can
be drastically reduced. This can be done by wearing gloves, using 70% EtOH liberally,
and keeping positive pressure on the syringe. The sampling protocol found in Appendix
H was used. A 1 mL sample was analyzed on the Vi-CELL each day of the study, starting
with day 0 and continuing through day 11. The sample collection was conducted around
the same time of day to keep consistency. The 1 mL sample was centrifuged at 1,000
RPM for 4 min. The supernatant was collected in a new microfuge tube to be used for
tPA quantification. The tPA sample was stored at -20°C until ELISA analysis (Appendix
F). Once the run was completed (day 12), the waste was sterilized and disposed of
following the protocol in Appendix H.

RESULTS
Shaker Flask Platform. For the shaker platform study, the cell density peaked on
day 7, ranging from 8.5 to 10.5 million cells/mL. The density was linked to the passage
number of the CHO 1-15 cell line. When comparing the three runs, run one had the
lowest passage number (or had been in culture the shortest amount of time (1 month) and
had only reached 8.5 million cells/ mL on day 7 as the maximum density (Figure 2-3)).
Run 3 reached 10.5 million cells/ mL and had been in culture the longest, closer to 3
months. Concluding that, the higher the passage, the higher the cell density on day 7. The
doubling times of the CHO 1-15 cells increase the longer they are kept in culture,
however, three months is the maximum amount of time the cells should be kept in
culture. The viability of the cells was maintained above 90%, which is consider healthy,
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until the maximum cell density was reached. Upon reaching maximum cell density, the
cell viabiltiy dramaticallly decreased as the cells entered the death phase.
The tPA quantity for the shaker study was measured using the established ELISA
assay (Appendix F). The maximum quantity of tPA produced was 2 mg per 100 mL,
which occurred between days 7 and 12 (Figure 2-4). That amount is right where the
standard tPA production level is produced at high quantites (47). The variation towards
the end of the growth curve was in part due to the % coefficient of variation (CV) values
in the ELISA assay. Anything less than 10% CV was acceptable to the TFS parameters
set for the collaboration objectives.

Figure 2-3: Cell density and viability growth curves for the shaker flask growth study.
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Figure 2-4: tPA production for the shaker flask growth study.

Bioreactor Platform (2 L). For the 2 L bioreactor growth studies, the cell density
peaked at day 5, with densities ranging from 14 to 17 million cells/mL (Figure 2-5). It
was observed that the maximum cell density increases the longer cells are in culture
(higher passage number). The viability was stable, remaining above 90% until the
nutrients were exhausted (Figure 2-6) and the cells reached stationary phase. The
viability decreased rapidly during the death phase of the growth curve. The glucose was
completely depleted from the media once the cells hit their maximum growth on day 5
(Figure 2-6). The lactate increased until day 5 showing that the glucose was being
metabolized by the cells (Figure 2-6). Table 2-2 shows an example (run 1) of the data that
is obtained from the bioprofile analysis.
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Figure 2-5: Cell density and viability growth curves for the 2 L bioreactor study.

Figure 2-6: Glucose and Lactate amounts during the course of the 2 L bioreactor CHO 115 growth studies.
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The tPA quantity was measured using the ELISA assay (Appendix F). The
maximum tPA quantity produced was around 24-26 mg per liter (Figure 2-7). The
maximum quantity of tPA produced occurred between days 5 and 6. The variation
towards the end of the growth curve was in part due to the % CV values in the ELISA
assay. Anything less than 10% CV was acceptable to the TFS parameters set for the
collaboration objectives.

Table 2-2: Example of the BioFLEX data from the 2 L bioreactor run 1 samples.
Day

pH

Glutamine
(mmol/L)

Glutamic
Acid
(mmol/L)

Glucose
(g/L)

Lactate
(g/L)

NH4+
(mmol/L)

Na+
(g/L)

K+
(mmol/L)

Ca++
(mmol/L)

0

7.49

4.42

2.19

8.58

0.01

3.27

88.4

7.72

0.16

1

7.40

3.84

2.21

8.01

0.22

4.02

90.4

7.88

0.17

2

7.35

3.29

2.32

7.47

0.74

4.69

90.9

7.68

0.17

3

7.30

2.28

2.58

6.43

2.19

5.65

106.8

7.51

0.17

4

7.32

0.86

2.72

3.50

4.02

5.40

122.9

6.30

0.16

5

7.58

0.62

2.77

0.02

4.92

3.81

139.0

5.25

0.14

6

7.81

0.92

3.72

0.01

3.80

5.66

136.7

6.68

0.15

7

7.79

1.15

4.19

0.00

3.34

6.30

132.9

6.97

0.18

8

7.80

1.25

4.49

0.00

3.33

6.75

136.1

7.25

0.21

9

7.70

1.24

4.56

0.00

3.32

6.95

136.4

7.32

0.22

10

7.78

1.24

4.60

0.01

3.27

7.19

141.8

7.61

0.24

11

7.81

1.21

4.59

0.00

3.33

7.26

142.6

7.65

0.24
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Figure 2-7: tPA production for the 2 L bioreactor study.

S.U.B. Bioreactor Platform (50 L). For the 50 L bioreactor growth studies, the
cell density peaked between days 5 and 6, with maximum densities the ranging from 12
to 15 million cells/mL (Figure 2-8). The discrepencies between the two runs is believed
to be due to the aggitation being shut off for 24 h on day 4 of the second run. Although
the oxygen was depleted without aggitation, the continual sparging of air allowed for
some stirring, which could explain why the cells did not die during that time. The cells
only grew from 8 million on day 4 to 12.4 million on day 5. It took 24 h to see the effect
the stress had on the cells, which presented as decreased tPA production (Figure 2-9). It
was believed that the cells were unable to recover fully because of the immense stress
and that is why they peaked on day 5 instead of continuing in logarithmic growth phase
and reaching closer to the expected to 16 million on day 6, as was the case during run 1.
The death phase started on day 6 and the cell density decreased dramatically, following
the trends of the previous run (run 1) and other runs in the 50 L bioreactor. In spite of the
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stress on the cells, the viability remained stable and healthy (above 90%) until the cells
reached death phase.

Figure 2-8: Cell density and viability growth curves for the 50 L bioreactor study.
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The maximum tPA quantity produced was 21-27 mg per liter (Figure 2-9). This
was higher than the expected 22 mg per liter (47) from CHO 1-15 cells in different media
and the base production of 20 mg per L from the shaker flasks. The maximum quantity of
tPA produced occurred between days 5 and 6. The variations between the runs can be
attributed to the error on day 4. Up to day 4, the amount of tPA production was very
similar between the two runs (Figure 2-9). The variation toward the end of the growth
curve was in part due to the % CV values. Nothing over a 10% difference was allowed
from TFS protocol standards. Also, comparing the 50 L S.U.B. runs to the 2 L bioreactor
runs, it can be observed that the tPA production can fluctuate, increasing and decreasing
slightly at the very end of the death phase. Although the second 50 L run did not reach
the level of cell density the first run did, it was successful as an operational qualification
run. The growth curve is still visible and the amount of tPA produced was substantial.

Figure 2-9: tPA production for the 50 L bioreactor study.
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DISCUSSION AND CONCLUSIONS
The average maximum amount of tPA quantity from the shaker platform was
19.8 mg per L. This would be the base value to compare the results to the platforms. The
tPA increases to 24.3 mg per L for the 2 L bioreactor and then to 30 mg per L for the 50
L (run 1 only). The cells reached the peak of the logarithmic growth phase faster when
using the bioreactors, day 5 for the 2 L and day 6 for the 50 L. This might be due to the
set up involved and the stress cells initally have when seeding such large volumes.
However, the ability to have more control over growth parameters with bioreactors does
increase the amount of protein production in cell lines.
The use of large scale bioreactors in the biomanufacturing industry is rising.
Large scale platforms allow for mass quantities of protein production,which leads to
increased profits for companies. For example, one run of a 2 L bioreactor with CHO 1-15
cells can produce 52 mg of tPA, while one run of a 50L S.U.B. can produce 1.35 g. The
cost of tPA is around $285 per 100µg (information found on http://sigmaaldrich.com), so
the difference in dollar amout of tPA between the 2 L and 50 L system is nearly $ 3.7
million.
Large scale bioreactors are sensitive to many factors. Protocols established in the
BioProcessing and Training Demonstration Lab will ensure that trained personnel with
access to quality equipment and materials will be able to achieve desirable results in their
own large scale bioreactor runs. The ability to control parameters such as % DO, pH,
agitation, and temperature allows the user to maximize protein production. Also the
convinience of working with disposable BPC’s allows for large scale bioreactors to be
used successfully in smaler scale labs with minimal equipment. It is recommended that
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this project move forward with one or two more runs using the 50 L S.U.B. in order to
verify the established protocols before scaling up to the 250 L S.U.B.
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CHAPTER 3
HEME-DERIVED ANTIOXIDANT COMPOUNDS

Oxidative stress is problematic in the industry of mammalian cell growth because
it causes down-regulation of protein production, slower growth, and potential for
decreased viability. Mesobiliverdin IXα (mesoBV IXα) is a compound similar to
biliverdin IXα (BV IXα) and has demonstrated anti-oxidant capabilities. Phycocyanobilin
(PCB) is another heme-derived compound that has anti-oxidant capabilities. This chapter
focuses on testing the anti-oxidant nature of the three heme-derived compounds: mesoBV
IXα, BV IXα, and PCB. Oxidative stress also causes a down-regulation of protein
production in cells. CHO cells are considered reliable and robust for high value
recombinant protein production. It is important to know how the heme-derived
compounds affect the growth, viability and protein production in the CHO 1-15 cell line.
The CHO 1-15 cell line expresses the protein tPA (human tissue plasminogen activator)
and secretes tPA into the media. The objectives for this project are as follows:


Use the trypan blue exclusion dye method to perform cytotoxicity assays
which include:
o Determine if mesoBV IXα, BV IXα, and PCB exhibit protection of
CHO 1-15 cells against oxidative stress after induced with a
stressor by measuring cell growth via the trypan blue method.
o Find the concentration of hydrogen peroxide and menadione that
will induce oxidative stress in the CHO 1-15 cell line by measuring
cell growth via the trypan blue method.
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o Find the optimal concentration of mesoBV IXα that displays no
toxicity to the CHO 1-15 cell growth and viability via the trypan
blue method.


Determine the effects that mesoBV IXα has on tPA production quantity
via the established ELISA assay.

MATERIALS AND METHODS
CHO 1-15 cell line. CHO 1-15 cells grown in suspension were obtained by TFS.
The cells were grown in an antioxidant modified HyCell CHO media (AM HyCell)
custom formulated by TFS and containing no additional antioxidant compounds. The
CHO 1-15 cells were grown at 37 °C, 95% humidity, 5% CO2 at 125 RPM. The protocol
for CHO 1-15 cell growth and maintenance is found in Appendix A. Cytotoxicity was
measured using the trypan blue exclusion dye method. Trypan blue 0.4% (TFS) was used.
Trypan blue can only penetrate cells that have damaged membranes (5). The percentages
of stained (dead) cells and unstained (alive) cells were calculated and the latter reported
as percent (%) viability. A Vi-CELL Cell Viability Analyzer (Beckman Coulter) was
used to determine the % viability of CHO cells and the total viable cell count per mL. A 1
mL cell sample was collected in the Vi-CELL sample cup. The Vi-CELL analyzed 50
images of the 1 mL sample and determined the average % viability and the total viable
cell count. The protocol for using the Vi-CELL is found in Appendix E.
tPA. The quantities of tPA produced were analyzed to examine the effects that
mesoBV IXα had on tPA production. One mL cell samples were collected for the tPA
ELISA and centrifuged at 1,000 RPM for 4 min. Samples were stored at -20°C until it
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was time to perform an ELISA. The concentration of recombinant tPA (in the
supernatant) was analyzed using the kinetic sandwich ELISA method
(www.enzymeresearch.com) and a SpectraMax spectrophotometer. The ELISA kit was
purchased from Enzyme Research Laboratories and included the capture and detecting
antibody. The standard was purchased from Calbiochem (cat #612200) for 100 µg of
tPA. The standard was re-suspended in sample diluent to a final concentration of 10
µg/mL. The ELISA protocol in Appendix F was used for the analysis.
Cytotoxicity measurements. Initially the cytotoxicity experiments were
performed in PETG Erlenmeyer shaker flasks (E-125) with a volume of 30 mL. In order
to test more variables during the same experiment and to conserve on materials and time,
a method using 6-well plates instead of shaker flasks was developed. Plate attachment
holders were used with the MAXQ 2000 platform shaker. A maximum volume of 4 mL
was used per well. The CHO cells were adapted for 24 h after inoculation in the plate
before experimental use (48). Varying concentrations of CHO cells ranging from 2.5 x
10⁵ to 2 x 10⁶ (6) (17) were also tested showing that the optimal seeding density was 5 x
10⁵ cells/mL. These concentrations allowed the cells to maintain logarithmic growth
during the course of the experiment. When cells were concentrated at higher cell density,
their sensitivity to induced oxidative stress decreased dramatically.
Heme-derived compounds. MesoBV IXα, BV IXα, and PCB were obtained
from D. Chen and J. Takemoto (Synthetic Bioproducts Center, USU). All three
compounds were obtained in powder form and required making solutions suitable for
sterile filtration prior to tissue culture use. The heme-derived compounds are structurally
similar so the methods for making solutions of them were similar. The method used was
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as follows: mesoBV IXα, BV IXα or PCB was prepared from powder into a high
concentration (1 – 100 mM) solution in 0.1 M - 0.2 M KOH with a pH between 10 and
12. Once in solution, the pH is lowered back to the range of 7–8 by dilution with AM
HyCell growth medium. The solutions were filtered sterilized before addition to the cell
suspension.
Oxidative stress of CHO 1-15 cells. The solution form of hydrogen peroxide (30
wt. % in H₂O) was obtained from Sigma Aldrich. The concentration range of H₂O₂ that
induced oxidative stress in the CHO 1-15 cells after 24 h is 500 µM to 5 mM. Menadione
was purchased from Sigma Aldrich. Menadione is a powder that is soluble in 100%
EtOH at 16 mg/mL, which is a concentration of 90 mM. After menadione was
solubilized, it was filter sterilized with a syringe 0.22 micron filter. The concentration of
menadione was kept higher so the amount used in each well was only a few microliters.
This ensured that the induced cellular stress was from the oxidant and not the ethanol.
The concentration range tested was 0 to 100 µM menadione.
Effects of heme-derived compounds. In order to test the three heme-derived
compounds ability to protect CHO cells from exposure to hydrogen peroxide, the cells
were plated at 500,000 cells/mL in 4 mL of AM HyCell CHO media in 6-well plates.
The cells were allowed to recover for 24 h while on a shaker platform in the incubator.
CHO cells were pre-treated for 30 min with mesoBV IXα, BV IXα, or PCB, at varying
concentrations, 0 µM- 50 µM, prior to exposure with the H₂O₂. A sample was taken 24 h
after exposure to the H₂O₂ to measure cell density and viability. The concentration range
of menadione toxicity was tested on CHO 1-15 cells. The range was 100 µM to 0 µM
menadione. The CHO 1-15 cells were seeded at a density of 5 x 10⁵ cells/mL in AM
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HyCell media and allowed to recover for 24 h. A sample for the Vi-CELL was taken 24 h
after exposure to menadione. To test the cytoprotective capabilities of mesoBV IXα, BV
IXα, and PCB to oxidative stress with menadione on CHO 1-15 cells, CHO 1-15 cells
were seeded at 2.5 x 10⁵ cells/mL in AM HyCell media in 6-well plates (4 mL per well).
The cells adapted to the culture in the incubator on the shaker platform for 24 h before
experimental use. MesoBV IXα, BV IXα, and PCB were added to the culture at a
concentration of 10 µM. After 30 min the menadione was added at a concentration of 15
µM. Cells were maintained at 37°C in an atmosphere of 95% air and 5% CO₂ at 120
RPM. A 1 mL sample was collected after 24 h and analyzed by the Vi-CELL to
document cell growth and viability. The toxicity effects of mesoBV IXα on CHO 1-15
cells growth and viability was tested. The cells were plated at 500,000 cells/mL in 4 mL
of media per well. The cells adjusted to the plating for 24 h in the incubator on the
platform shaker. The mesoBV IXα was solubilized to a 1 mM concentration and added to
each well with increasing concentrations. A 1 mL sample for each concentration was
collected after 24 h and 48 h for the Vi-CELL analyzer. The experiment to test the effects
on tPA production in CHO 1-15 cells after exposure to mesoBV IXα was set up using E125 shaker flasks. The media used was the AM HyCell CHO. Cells were seeded at
250,000 cells/mL. The three parameters tested were the control, mesoBV IXα added on
day 0, and mesoBV IXα added on day 0 and again on day 5. A 1 mL sample was
collected for the Vi-CELL and a 1 mL sample was centrifuged at 1,000 RPM and the
supernatant was saved for the ELISA protocol (Appendix F).
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RESULTS
The experiment shown in Figure 3-1 shows the results of testing the three hemederived compounds on CHO cells exposed to hydrogen peroxide. MesoBV IXα, BV
IXα, and PCB did not exhibit cytoprotective capabilities when CHO 1-15 cells were in
oxidative stress induced with H₂O₂ (Figure 3-1). Both the 500 µM and the 5 mM
concentrations of H₂O₂ induced the CHO 1-15 cells into oxidative stress by dramatically
slowing cell growth when compared to the control. When a heme-derived compound was
added in combination with hydrogen peroxide, no cytoprotective effects (seen as reversal
of the H2O2 inhibitory effects) were observed. With increasing concentrations of
mesoBV IXα, BV IXα, and PCB in the absence of H2O2, dose response decreases in cell
growth were observed.

Figure 3-1: Cytoprotective capabilities of BV IXα, mesoBV IXα, and PCB on CHO 1-15
cells after induction of oxidative stress with H2O2.
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Since cytoprotective capabilities against H₂O₂ were not observed, it was
important to test another oxidative stressor, menadione. Menadione can cause oxidative
stress through mechanisms that differ from those caused by H₂O₂. The optimal
concentration for inducing oxidative stress with menadione was unknown in the CHO 115 cell line. The concentration range tested was 100 µM to 0 µM menadione. The
threshold menadione concentration for causing oxidative stress was 15 µM (Figure 3-2),
and this concentration was subsequently used.

Figure 3-2: Exposure of CHO 1-15 cells to menadione and the effects on the
viability of cells after 24 h.
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The purpose of this experiment was to induce cellular oxidative stress to
demonstrate the antioxidant effects of the heme-derived compounds by measuring the
growth and viability. In this case the oxidant used was menadione. The results of the
experiments with menadione are contained in Figure 3-3. Again it is demonstrated that
the heme-derived compounds do not exhibit cytoprotective capabilities when the CHO 115 cell line is induced to oxidative stress. According to the Beckman Coulter Vi-CELL
instrument guide, the cell analyzer has an expected coefficient of variance of 6%. This
means that the counting accuracy of the Vi-CELL is + or – 6%. This is a low variance %
compared to other automated counters. Therefore, it is safe to assume based on the
results in Figure 3-3 that when mesoBV IXα, BV IXα, and PCB were added with
menadione, the inhibition of cell growth was greater than when menadione was added to
the well alone.

Figure 3-3: Cytoprotective capabilities of mesoBV IXα, BV IXα , and PCB on
CHO 1-15 cell after induction to oxidative stress with menadione.
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The results with H₂O₂ indicated that an increasing concentration of either
mesoBV IXα, BV IXα, or PCB inhibits CHO 1-15 cell growth. The results with
menadione demonstrate that the heme-derived compounds also exacerbated the
inhibitory effects of this oxidant. The question arose: Are these heme-derived
compounds alone toxic to CHO 1-15 cells? MesoBV IXα at concentrations ranging
from 0-100 µM were examined for inhibitory effects on CHO 1-15 cell growth. The cell
density and viability is show in Figure 3-4.

Figure 3-4: Toxicity effects with increasing concentrations of mesoBV IXα on
CHO 1-15 cells growth and viability.
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The results in Figure 3-5 show the tPA quantity from three different parameters.
The flask with mesoBV IXα added on day 0 and day 5 had a decrease in tPA production
after the second dose on day 5. The control and the flask with mesoBV IXα added only
on day 0 had very similar levels of tPA production. The tPA quantity decreased in the
flask that the mesoBV IXα was added twice because the cell density and viability
decreased after the second addition of mesoBV. The cell density on day 8 for the
mesoBV IXα added on day 0 and 5 was 1 x 10⁶ cells/mL and the mesoBV IXα added
only on day 0 was 8 x 10⁶ cells/mL (Figure 3-5).

Figure 3-5: The effects on tPA production in CHO 1-15 cells after exposure to
mesoBV IXα.
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DISCUSSION AND CONCLUSIONS
Inducing oxidative stress in the CHO 1-15 cell line was measured by cell injury,
slowed growth or death. The cytotoxicity studies focused on two different stressors:
H₂O₂ and menadione. Those compounds have been shown to induce oxidative stress in
CHO cells and can cause apoptosis or necrosis. The first oxidant tested was hydrogen
peroxide. The publication that was the model of the oxidative stress experiments used
primary cell cultures (55). It required higher concentrations of hydrogen peroxide to
induce oxidative stress in the CHO 1-15 secondary cell line. The heme-derived
compounds did not inhibit oxidative stress in CHO 1-15 cells, which are immortalized
cells, when measured with the trypan blue method. Those results were opposite from
those with primary cells and mesoBV IXα. The mesoBV IXα protected primary cells
from oxidative stress (12) (49). This indicates that there is a major difference between
secondary cells and primary cells and the way oxidative stress affects them.
Oxidative stress causes a down-regulation of protein production in cells. CHO
cells are considered reliable and robust for high value recombinant protein production. It
is important to know how the heme-derived compounds effect protein production in the
CHO 1-15 cell line. The CHO 1-15 cell line expresses tPA and secretes the tPA into the
media. The quantity of tPA was analyzed to examine the effects that mesoBV IXα had on
tPA production. MesoBV IXα at a 10µM concentration had no effect on the tPA
production when exposed one time to the CHO 1-15 cells.
As a secondary cell line, CHO cells have been propagated in culture for many
generations and have evolved to divide continuously. In essence, they have achieved an
immortalized state of growth and existence. Such a state provides one possible
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explanation for why the heme-derived compounds did not protect CHO 1-15 cells from
oxidative stress. It may be speculated that they have developed a high degree of
resistance or tolerance to oxidative stress. A recent publication (51) has shown that
biliverdin’s antioxidant capabilities by scavenging of reactive oxygen species (ROS)
inhibit the growth of immortalized cancer cells. ROS-mediated cellular signaling is
critical for oncogenic pathways that promote cellular growth (51). Furthermore, increased
oxidative stress in cancer cells upregulates growth factors HIF1-a and VEGF that are
necessary for angiogenesis (51). Therefore, it is hypothesized that CHO 1-15 cells behave
very similarly to cancer cells, which are also considered to be immortal. This could
explain why the heme-derived compounds experiments described above inhibited the
growth. ROS activity was not measured in the current work; only cell growth via trypan
blue method was measured. It is speculated that heme-derived compounds scavenge ROS
which in turn impedes the growth of the CHO 1-15 cell line. This scenario might also
explain why a high concentration of hydrogen peroxide is required to inhibit CHO 1-15
cell growth. Since immortal cells use ROS for cell signaling pathways for growth, the
hydrogen peroxide at lower concentrations might have been beneficial to the cells.
However, at higher concentrations there was a toxic effect. Future experiments would
need to measure the ROS levels in the normal CHO cell line, the induced oxidative stress
cell line, and the cell lines treated with mesoBV IXα.
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CHAPTER 4
SILK GLAND CELL CULTURE

There are no publications on developing a cell line from spider silk producing
cells. A cell line from one of the spider silk producing glands should have the capacity to
secrete full-length native proteins, which could range in size from 200 kDa to 500 kDa,
possibly larger. The common disadvantage of all heterologous expression systems
attempted for producing spider silk is they produce only fragments of the spider silk
proteins that have decreased mechanical properties. An immortalized silk producing cell
line that produces full-length proteins could be the solution for the large-scale production
of spider silk. Also, a cell line capable of producing very large proteins would have broad
utility beyond simply the production of full length silk proteins.
Nephila clavipes is an orb-weaving spider which has six different silk producing
glands and one glue producing gland (26). Silk proteins (spidroins) produced by the six
different silk glands generally have relatively high molecular weights of 200 K to over
350 K (27). The synthesis of these spidroins occurs in columnar epithelial cells (26). The
major ampullate glands are the most studied of the six different glands due to the
mechanical ability of the silk the glands produce. The major ampullate silk has two
proteins: Major ampullate spidroin 1 (MaSp1) and Major ampullate spidroin 2 (MaSp2).
These proteins are extremely large, with molecular weights between 275 K and 320 K
(22).
Due to the seasonal nature of spiders (only available in the fall months) the same
techniques of isolating a cell line to primary culture from the silk producing glands of the
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silkworm Bombyx mori (available year around) were also explored. Such a system
permits making silk producing cell lines when adult spiders are not available. Although
many cell lines have been developed from B. mori, none have ever been reported from
their silk producing glands. B. mori is the domesticated larva of the silkworm moth. The
silkworm produces a twin-thread of silk fibroin, secreted by gland cells. There are two
silk glands per worm. The silk gland is made up of three zones: anterior, middle and
posterior. Only the middle and posterior parts have cells that secrete very large silk
fibroins of up to 350 kDa. These cells would be useful for high-level expression of large
proteins. The results would have similar benefits in terms of silk production as a spider
silk gland derived cell line.

MATERIALS AND METHODS
Insect cell culture success is dependent upon antibiotics, improved medium, and
patience (41). The methods for establishing primary (finite) and secondary (continuous)
insect cell lines are still poorly developed (43). Primary insect cell culture has been
achievable. Most insect cell culture success (80%) is usually from the Lepidoptera and
Diptera species at a larva stage. There are not many published successes from adult
insects and only one from adult spiders. Since the methods are premature, trial and error
will be the way to find the optimal medium and cell line maintenance procedures. The
base media used was chosen from a paper that discusses the techniques used to start a
new insect cell line from the Spodoptera exigua using TNM-FH media with 10% FBS.
TNM-FH is a low cost, common media (52). Antibiotics are critical in the success of
insect cell culture because of the high risk of contamination culturing a primary insect
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cell line holds. A publication that was successful in culturing epithelial venom gland cells
for 48 h and muscle gland cells for up to 6 months in culture was used as the basis for
supplements to the TNM-FH media (53). The supplements and antibiotics were prepared
and filtered sterilized before addition to the media at the following concentrations:
gentamicin (10 µg/mL), amphotericin (0.25 µg/mL), tetracycline (10 µg/mL), oxaloacetic
acid (9.5mM), insulin (8.3 µg/mL), and 10% fetal bovine serum (FBS).
Various methods were attempted to generate major ampullate cells in primary
culture. Below describes the best method to date. An adult N. clavipes spider was
disinfected by submerging the entire live spider in 70% EtOH for 3-5 min. The
cephalothorax was removed from the body and placed in a sterile petri dish to be used
with a dissection microscope. SSC (sodium citrate) pH 7.0 was used when removing the
glands from the cephalothorax. The paired major ampullate glands were removed. Figure
4-1 shows a major gland after it is isolated from the spider. Although the major
ampullate glands were the focus of this study, the piriform and minor glands were
harvested after the major glands were harvested. The glands were placed in a
microcentrifuge tube in 400 µL of TNM-FH medium with supplements (antibiotics and
serum) but no FBS, since the FBS inactivates the proteolytic enzymes. The glandular
tissue was minced with dissection scissors in the tube. After the tissue was minced the
tissue was digested with proteolytic enzymes in order to yield single cells. Two hundred
µL of 0.05% trypsin plus 0.02% EDTA solution was added and incubated at 37°C for 5
min. Then collagenase (400 µL) was added to the microcentrifuge tube for at a final
concentration of 1 mg/mL and incubated at 37°C for an additional 10 min. Medium with
FBS (100 µL-300 µL) was added to the tube before the cells were centrifuged at 218 X g
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for 4 min or 10 X g for 10 min (10 X g was less harsh and more successful). The
supernatant was discarded and the cell pellet was gently washed with 100 µL of medium
with supplements (antibiotics and serum). This wash is important to remove
contamination. The wash was centrifuged again at 218 X g for 4 min or 10 X g for 10
min following the same speed from the first spinning. The supernatant was discarded and
the cell pellet was re-suspended gently in medium and was then filtered with a cell
strainer into a 50 mL conical vial before addition to a T25 cm² flask with a final volume
of medium of 2 – 3 mL. The cells were kept at 27°C and 5 % CO₂.
About 500 µL to 1 mL of media was added to the flasks once every 7 days. It was
found that leaving the cells alone and manipulating the flasks less often helped increase
the survival of the cells. Since the venom gland paper was only successful with isolated
epithelial gland cells in culture for 48 h it was thought to treat our primary cells with a
mutagen as soon as possible as an attempt to preserve and mutate the cells to divide
continuously (53). The chemical, MNNG, a mono-functional alkylating agent that causes
chromosomal DNA damage, has been used as a chemical transformation means for
immortalizing mammalian cells and has been used successfully for transforming insect
cells from a primary to a secondary culture (43). Unfortunately, MNNG is unobtainable
in the U.S., but a similar mutagen, MNU is recommended by Sigma Aldrich and is
available for use in the U.S. Based on the literature the concentration of MNU was 3
µg/mL and added to a flask of cells for 3 days (43).
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Figure 4-1: Major ampullate gland isolated from Nephila clavipes

A western blot analysis was done on the major ampullate gland cells. In order to
classify these cells, a small scraping of cells plus any protein surrounding them was
collected in 500 µL of medium at 19 weeks in culture. The sample was centrifuged for 18
min at 14,000 RPM. The cell pellet was re-suspended in sample buffer with urea (SABU)
and prepped for a western blot analysis. The samples were prepared first by sonication
for three seconds and added in a 1:1 ratio of SABU to sample. Then the samples were
boiled for 10 min. Samples were loaded on a TRIS-HEPES gel at 20 µL each well. The
gel was run for 8 h at 40 V then 3 h at 50 V. The gel was transferred to PVDF plus paper
and blocked in milk solution for 30 min. Spider silk conserved C-termini polyclonal
antibody (M4, Pacific Immunology) was added at 1:1000 dilution for 30 min. The PVDF
paper was quickly washed two times and a third time for 5 min with agitation. The
secondary antibody was a donkey anti-rabbit IgG labeled with alkaline phosphatase (AP)
for detection at 1:2850 dilution in TBS-T20 with milk was added for 30 min with
agitation. The membrane was washed quickly two times and for 5 min on the third wash.
One step developer for AP was added for 2 min.
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The method for isolating the silk worm silk gland cells differed from that for
spider silk glands. The media was the same as the spider silk media with the only
difference being the percent of FBS, 20% was used instead of 10%; 20% is typically used
for primary B. mori cells to promote cell proliferation. The silkworm was sterilized for 3
min in 70% EtOH before dissection. All tools were sterilized and dissections took place
in a sterilized laminar flow hood. The worms were pinned down (head and tail) onto
sterile Styrofoam with dorsal side up. An incision in the middle of the dorsal side was
made from the tail all the way to the head just under the surface of the skin making sure
no other parts of the worm were cut to avoid contamination. This exposed the silk glands,
and the middle and posterior zones of the glands were isolated and placed in a
microcentrifuge tube containing PBS. The glands were rinsed twice and then placed in a
fresh microcentrifuge tube with medium (500 µL). The glands were minced with scissors
and then plated in T-25 cm² for growth (2 silk glands per flask). Another method of for
harvesting the cells from the glands was attempted. The glands were minced with
scissors then digested with a 0.05% trypsin plus 0.02% EDTA solution for 5 min,
centrifuged at 10 x g for 10 min and filtered through a cell strainer before plating.
A “Cells to PCR” kit from Invitrogen (SuperScript II cells direct) was used to
classify the cells from the silk worm gland as silk producing cells. The mRNA was
isolated from the cells and first strand cDNA synthesis was performed using the kit. PCR
was performed using the GoTaq kit and primers designed to prime the DNA of the B.
mori silk fibroin (Figure 4-2) The reaction mixture (30 µL) contained 15 µL GoTaq, 1.5
µL cyber green, 1 µL of forward and reverse 10 mM primer, 6.5 µL of H₂O and 5 ng of
template DNA. The reactions were carried out in a thermal cycler using the following
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conditions. (i) 94°C for 3 min, 1 cycle; (ii) 94°C for 1 min, 65-51°C for 30 s, 72°C for 45
s, 37 cycles; (iii) 72°C for 5 min, 1 cycle. The temperature gradient used for the PCR
reaction ranging between 65°C to 51°C between eight reactions. The target size of DNA
is 372 bp.

RESULTS
Successful cell cultures from the major ampullate gland are shown in Figure 43A. Major ampullate cells adhered to the tissue cultured treated T-25 cm² flask. The cells
secreted a matrix that increased adherence to the flask. Unfortunately, the matrix was so
strong that proteolytic enzymes used to harvest cells, such as trypsin, collagenase, and
elastase, did not work to break up the matrix. As a result, cells were unable to detach
from the flask for passaging. Using a cell scraper killed the cells and did not remove all
of the matrix. As time passed, the cells surrounded by the matrix died (Figure 4-3B). To
prevent cells from adhering to the flask and secreting their matrix, the cells were placed
on a shaker platform immediately after harvested from the spider.

Figure 4-2: A DNA sequence of silk fibroin from the Bombyx mori. The bases shown in
red are where the primers annealed.
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Images of the major ampullate cells that were plated and placed immediately on
the shaker platform are shown in Figure 4-4. Those cells in Figure 4-4 were treated with
MNU 10 days after isolation into primary culture. The cells looked healthy and the
shaking did not harm the cells. The shaking did not prevent the cells adherence to the
flask, although the attachment was lighter and the matrix did not form as in Figure 4-3.
These cells survived in culture for 6 months. The growth seemed to slow or stop after 6-8
weeks. The cells were maintained by adding only 1 -2 mL of fresh medium per week and
replacing all the medium after 6–8 weeks.

Figure 4-3: A) cells from the major ampullate gland in culture for 3 weeks shown at high
magnification (40 x). B) Dead cells from the major ampullate gland in culture for 3
months shown at high magnification (40 x) surrounded by protein matrix secreted by
cells that prevented cell-growth and sub-culturing.
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Figure 4-4: Major ampullate cells. A and B were images taken after the cells were 5
weeks in culture with high magnification (40 x). C was taken 13 weeks in culture at high
magnification. D was taken 19 weeks in culture at high magnification (40 x).

In western blots, major ampullate cell extracts showed a purple smear throughout
the entire lane. Expected sizes for full length spider silk protein were between 200 kDa
to 350 kDa. Although the blot staining intensities were greater around the 250 kDa and
higher areas, a discrete and cleared stained protein band was not seen (Figure 4-5). This
may have resulted from the mixture of cells at different stages of protein production.
Cells in culture do not behave the same as in their natural environment. Mutations may
have altered the cells ability to produce full length silk proteins. The cells may have
stopped producing silk and stopped growing because they were not successfully
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immortalized. The purple smear might be from the proteins inside the cells that stopped
growing and what was adhered to the flask. This could explain why the cells are not
secreting the proteins into the media anymore. The positive results do indicate that the
cells grown in culture for several months were major ampullate gland cells.

Figure 4-5: Western blot analysis with major ampullate cells after they had been
in culture for 5 months. Lane 1- Precision Plus marker (Bio Rad), lane 2- major
ampullate cell sample, lane 3-media from major ampullate cell flask, lane 4media control.
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The piriform and minor gland cells were isolated from N. clavipes. Once isolated
into culture, neither had the abundance or potential that cells from the major ampullate
demonstrated. The morphologies of the piriform and minor cell types are shown in Figure
4-6. The minor gland cells had a similar protein matrix problem, no other cell types
secreted a matrix like the major ampullate cells did. The matrix problem with the minor
glands was prevented by placing the flask on a shaker platform after isolation. The cells
from the piriform gland did not show any cellular growth. It might be that the T-25 cm²
flask was too large of a surface area for the small cells to attach and continue growing
(Figure 4-6).

Figure 4-6: A cells from the piriform gland at high magnification (40 x). B cells from the
minor ampullate gland at high magnification (40 x).
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The results pictured in Figure 4-7 are cells from the B. mori silk gland. The
silkworm silk gland cells are larger than the silk gland cells from the spider. The cells in
Figure 4-7A are from the mincing only method and were not digested with any
proteolytic enzymes. The cells were surrounded with tissue and plated with heavy
amounts of tissue debris. It was difficult to yield single cells. Figure 4-7B are cells that
were minced with scissors then digested with a 0.05% trypsin plus 0.02% EDTA solution
for 5 min, centrifuged at 10 x g for 10 min and filtered through a cell strainer before
plating. There was a decrease of unwanted tissue/debris with this method although there
were still not many single cells.

Figure 4-7: Living cells from the silk glands from the B. mori. A) gland cells plated after
mincing with scissors only. B) gland cells that were digested and filtered through a cell
strainer before plating.
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The results in Figure 4-8 are from a gel run from a PCR reaction with template
DNA from B. mori cells isolated in primary culture. The expected size was 372 bp and is
shown positive in Figure 4-8. The mRNA was extracted from the silk gland cells in
primary culture to yield template cDNA. PCR was performed with primers that are
designed to amplify the DNA sequence from B. mori silk (Figure 4-8). The cells isolated
into primary culture are from the B. mori silk gland. These results demonstrate the
potential silk gland cells have to produce silk in culture as indicated by the presence of
the messenger sequences.

Figure 4-8: Gel electrophoresis results from a PCR reaction with DNA from silk gland
cells. The first lane is the marker, lane 2, DNA from a PCR reaction with annealing
temperature of 65°C, lane 3, annealing temperature of 64.2°C, lane 4 at 62.6°C, lane 6 at
59.9°C, lane 7 at 56.5°C.
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DISCUSSION AND CONCLUSIONS

The primary cell line from spider major ampullate gland cells appeared viable in
culture for about 6 months. Primary culture of major ampullate gland cells has never been
reported in the literature. The work with getting a secondary silk producing cell line in
culture should continue. Major ampullate glands should be isolated from at least 4 adult
spiders before placing in a T-25 2 flask. If fewer glands are isolated, then plating in
smaller plates (24-12 well) would have a better chance of success. Also, keeping the cells
on the shaker is beneficial and should continue. The concentration of the mutagen or its
time of exposure might be increased. Other methods besides using MNU might have a
positive result also.
The cells from the silkworm gland are the first native silk producing cells in primary
culture. Many cell lines have been developed from B. mori, although it usually takes
several months to years to develop a secondary cell line. The use of MNU to immortalize
B. mori cells has not been reported in the literature. Successfully using the MNU
compound to immortalize the primary cells could change the way that insect cell lines are
immortalized. It is recommended to continue the research with silk worm gland cells.
These animals are available all year long. Multiple cell lines have been developed from
the B. mori. There are a lot of published protocols on starting cell lines from other parts
of the silk worm. The silk gland cells from the silk worm are able to be isolated into
primary culture. Methods for immortalizing it can be developed to make a secondary cell
line.
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Not only would a native silk producing cell impact spider silk production but also be
used to further insect cell recombinant technology production. It has been demonstrated
that insect cell lines are good choices for expression of recombinant molecules, including
antibodies (54). In some cases, expression levels with insects are higher than with
mammalian cells (54). Insect cells have the capability of post-translational modifications
that would need to be provided by a eukaryotic cell (54).
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS

PART 1: CHO 1-15 GROWTH STUDIES
The use of large scale bioreactors in the biomanufacturing industry is rising.
Large scale platforms allow for mass quantities of protein production,which leads to
increased profits for companies. For example, one run of a 2 L bioreactor with CHO 1-15
cells can produce 52 mg of tPA, while one run of a 50L S.U.B. can produce 1.35 g. The
cost of tPA is around $285 per 100µg (reference), so the difference in dollar amout of
tPA between the 2 L and 50 L system is nearly 3.7 million dollars.
Large scale bioreactors are sensitive to a varity of factors. Protocols established in
the BioProcessing and Training Demonstration Lab will ensure that trained personnel
with access to quality equipment and materials will be able to achieve desirable results in
their own large scale bioreactor runs. The ability to control parameters such as % DO,
pH, agitation, and temperature allows the user to maximize protein production. Also the
convience of working with disposable BPC’s allows for large scale bioreactors to be used
successfully in smaler scale labs with minimal equipment.
The average maximum amount of tPA from the shaker platform was 19.8 mg per
L in HyCell CHO media. This media has never been used with the CHO 1-15 cell lines in
the large scale platforms. That would make the 19.8 mg average from the shaker flask the
base value to compare the results to the platforms. The tPA increases to 24.3 mg per L for
the 2 L bioreactor and then to 30 mg per L for the 50 L (run 1 only). The ability to have
more control over growth parameters with bioreactors does increase the amount of
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protein production in cell lines. It is recommended that this project move forward with
one or two more runs using the 50 L S.U.B. to get a better idea of the amount of tPA
produced in a 50 L S.U.B. from the CHO 1-15 cell line in HyCell media. It would be
expected that the maximum amount of tPA in the 250 L S.U.B. would be higher than the
50 L. Experiments done in the 250 L S.U.B. can verify that claim.

PART 2: HEME-DERIVED ANTIOXIDANT COMPOUNDS
As a secondary cell line, CHO cells have been propagated in culture for many
generations and have evolved to divide continuously. In essence, they have achieved an
immortalized state of growth and existence. Such a state provides one possible
explanation for why the heme-derived compounds did not protect CHO 1-15 cells from
oxidative stress. It may be speculated that they have developed a high degree of
resistance or tolerance to oxidative stress. A recent publication (51) has shown that BV
IXα's antioxidant and scavenging of ROS capabilities inhibit the growth of immortalized
cancer cells. ROS-mediated cellular signaling is critical for oncogenic pathways that
promote cellular growth (51). Furthermore, increased oxidative stress in cancer cells
upregulates growth factors HIF1-a and VEGF that are necessary for angiogenesis (51).
Therefore, it is hypothesized that CHO 1-15 cells behave very similarly to cancer cells,
which are also considered to be immortal. This could explain why the heme-derived
compounds experiments described above inhibited the growth. ROS activity was not
measured in the current work; only cell growth via trypan blue method was measured. It
is speculated that heme-derived compounds scavenge ROS which in turn impedes the
growth of the CHO 1-15 cell line. This scenario might also explain why a high
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concentration of hydrogen peroxide is required to inhibit CHO 1-15 cell growth. Since
immortal cells use ROS for cell signaling pathways for growth, the hydrogen peroxide at
lower concentrations might have been beneficial to the cells. However, at higher
concentrations there was a toxic effect. Future experiments would need to measure the
ROS levels in the normal CHO 1-15 cell line, the induced oxidative stress cell line, and
the cell lines treated with mesoBV IXα.

PART 3: SILK GLAND CELL CULTURE
Not only would a native silk producing cell impact spider silk production but it
could also be used to further insect cell recombinant technology production. It has been
demonstrated that insect cell lines are good choices for expression of recombinant
molecules, including antibodies (54). In some cases, expression levels with insects are
higher than with mammalian cells (54). Insect cells have the capability of posttranslational modifications that would need to be provided by a eukaryotic cell (54).
Primary culture of major ampullate gland cells has never been reported in the
literature. The work with getting a secondary silk producing cell line in culture should
continue. The major ampullate gland is the largest of the glands in the spider and is the
most studied. The main focus should be on the major ampullate gland and not the other
glands. This will make it easier when isolating into primary culture. Major ampullate
glands should be isolated from at least 4 adult spiders (8 glands) before placing in a T-252
flask. If fewer glands are isolated, then plating in smaller plates (24-12 well) would have
a better chance of success. Also, keeping the cells on the shaker is beneficial and is
recommended. The concentration of or length of exposure to the mutagen might be
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increased. Other methods besides using MNU might have a better chance of success,
since the use of MNU for immortalizing insect cell lines is not well studied.
The cells from the silk worm gland reported here are the first native silk producing
cells in primary culture. Many cell lines have been developed from B. mori, although it
usually takes several months to years to develop a secondary cell line. Developing the
silk gland cells of the B. mori has a better chance of success than from the spider. These
worms are available all year long unlike the spider which is only available in the fall
months. The glands come from a larval stage while the glands from the spider come from
the adult. Multiple cell lines have been developed from B. mori. There are a lot of
published protocols on starting cell lines from other parts of the silk worm. Also there are
many papers and protocols to try for isolating cells from B. mori into culture. The use of
MNU to immortalize B. mori cells has not been reported in the literature. Successfully
using the MNU compound to immortalize the primary cells could change the way that
insect cell lines are immortalized. It is recommended to continue the research with
silkworm gland cells. Methods for immortalizing them can be developed to make a
secondary cell line.
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MAINTENANCE OF CHO 1-15 CELLS IN HYCELL MEDIUM (adapted from
Thermo Fisher-Scientific)
Purpose. To keep cell cultures at an optimal density for continued growth and to
stimulate further proliferation, the culture must be divided and fresh medium supplied.
Materials.


PETG shaker flasks, E-125, E-250, E-500



Pipettes (varying sizes)



Vi-CELL sample cup



HyCell CHO growth Media (TFS)



Vi-CELL analyzer (Beckman Coulter)



Laminar flow hood

Procedure.
1. Passaging. It is critical to passage the CHO 1-15 cells while they are in log phase
growth. Passaging should be done routinely and take place every 3-4 days when
flasks have been seeded at 250,000 cells/mL. For example: passage cells every
Monday and Friday to maintain healthy cells and keep in log growth phase.
2. When the cells are ready for passaging tighten lid on flask and remove the shaker
flask from the incubator and place flask in the laminar flow hood. Do not open
the flask until in the sterile laminar flow hood.
3. Maintain aseptic technique at all times when handling mammalian cells. Take a 1
mL sample from the culture shaker flask using a sterile pipette and sterile
technique, dispense into a Vi-CELL sample cup. Make sure the cell media
mixture is uniform and that cells have not settled down on bottom of flask. If
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cells have settled down before taking the sample, swirl the shaker flask to evenly
distribute the cells in the media.
4. Use the Vi-CELL machine following the Vi-CELL protocol to get cell count and
viability.
5. Cell Count. From the Viable cells/ mL, determined by the Vi-CELL sample,
calculate the split ratio required to seed a new shaker flask with 250,000 cells/ mL
depending on the desired final volume of new shaker flask.
a. You can calculate your split ratio using the formula: (V1)(C1)=(V2)(C2).
Where;
V1= the volume of spent media needed to seed new flask.
C1= the density of spent media.
V2= the desired final volume of media in new flask.
C2= the seeding density of media in new flask.

6. Aseptically transfer the required number of cells to the new shaker flask with the
appropriate volume of new media.
7. Loosen the caps of the culture flasks to allow for proper gas exchange (or use a
gas-permeable cap), and return the flasks to the shaking incubator. The shaking
speed for the maxQ platform shaker platform is 100-150 RPM
8. Label each PETG shaker flask with the following information; (1) date out of
cryo + cell line i.e. 010101CHO1-15, (2) date of split, (3) media, (4) initials.
Note. Do not keep cells in culture longer than 3 months from out of cryo date.
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THAWING CELLS FROM CRYOPRESERVATION AND CELL CULTURE
SCALE-UP (adapted from Thermo Fisher-Scientific)
Purpose. To outline the procedure for cell culture scale-up.
Materials.
CO₂ Incubator
Biological Safety Cabinet
Vi-CELL analyzer
Pipettes varying sizes
T-25 Flask
Erlenmeyer flask varying sizes
Procedure. All work should be done in a laminar flow hood with aseptic technique.
Thaw cells.
1. Remove a cryo vial of frozen CHO cells from the cryo tank filled with liquid
nitrogen. Wear safety glasses or a mask shield when working with cryo vials.
Make note of which cryo vial you remove.
2. Immediately thaw cells under running warm tap water. Make sure not to get
water by the cap of the cryo tube as to maintain sterility.
Re-suspend cells.
3. Once the vial is thawed spray the outside of vial with 70% EtOH and continue
work inside the laminar flow hood.
4. Add 5-7 mL of HyCell CHO media to a sterile 15 mL conical tube. Add the
thawed cells from the cryo vial to that 15mL tube.
5. Centrifuge the media cell mixture at 1,000 RPM for 4 min.
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6. Discard the supernatant and re-suspend the cell pellet in 7 mL of HyCell media.
This will remove the unwanted DMSO so cells can recover and grow in culture.
7. Immediately plate the cells in a T-25 flask by adding the 7 mL of media cell
mixture to the T-25 flask.
8. Label flask as follows: (1) date out of cryo + cell line i.e. 010101CHO1-15 (2)
date of split (3) media (4) initials. Immediately put flask in a CO₂ incubator at
37°C.
Cells in suspension.
9. After 2-4 days remove cells from T-25 flask and start the up-scale process by
transferring cell/media mixture to a 125 shaker flask.
10. Make the final volume of media from 30 mL- 50 mL. Maintain cells following
the protocol for CHO 1-15 maintenance.
Up-scale cells.
11. Count cells every 3 - 4 days. When cells are confluent enough to passage, seed
them in the highest volume of complete media using the appropriate seeding
density for the cell line being worked with. To calculate how much you will need
to seed a bigger flask use the following calculation:
Seeding density you want / viable cells/mL x volume you want to achieve. This
will give you the volume of culture to seed the new flask. Take that volume and
subtract it from the total volume desired this will give the volume of fresh media
to add. Use the table below to find the appropriate flask:
Flask
T-25 – 7 mL
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125 mL Erlenmeyer – 50 mL
250 mL Erlenmeyer – 100 mL
500 mL Erlenmeyer – 200 mL
2800 mL Erlenmeyer (Fernbach Flask) – 800 mL
Repeat the process as necessary to reach the desired scale-up
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CRYOPRESERVATION PROTOCOL (adapted from Thermo Fisher-Scientific)
Purpose. The purpose of this procedure is to establish a method for preserving the CHO
1-15 cell line.
Materials.
Sterile conical centrifuge tubes 15ml and 50ml
Nalgene cryo vials
Cryo marker for labeling
DMSO
70% isopropanol
centrifuge
Procedure. All work with open cultures and media should be done under a hood. Cells
to be cryopreserved should be maintained in mid-log phase and at a 90 % or higher
viability.
1. Cryopreservation Medium Preparation. Use 7.5 % v/v DMSO final concentration
to the cell medium being used. Make sure the DMSO is sterile.
2. Use a cryo marker to label the desired number of cryo vials with cell name, date
frozen, cell concentration, and DMSO %.
3. Determine cell Determine cell concentration using the Vi-CELL protocol.
Adjust the cell concentration so it is between 2 x 10⁶ cells/mL and 7 x 106
cells/mL. Centrifuge suspended cells at 1,000 x RPM for 4 min and re-suspend
in sterile cryopreservation medium. Work should proceed quickly to minimize
length of time cells are exposed to the DMSO which acts as the cytoprotective
agent.
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4. Place 1-1.5 mL of the cell suspension in each sterile ampule by using a sterile
pipet and tighten the lid.
5. Fill the Biotech apparatus with fresh isopropanol (if level is low).
6. Place sealed ampules into the Biotech apparatus and cool at an approximate rate
of 1 °C/min by placing the unit into an ultra-low freezer that is kept at -70 °C or
colder. The apparatus must remain in the ultra-low freezer for at least 18 h.
7. Put on protective wear, safety glasses or face shield and remove the Biotech
apparatus from the ultra-low freezer.
8. Remove ampules from Biotech apparatus, wipe off alcohol, place in numbered
canes and place canes in the liquid nitrogen freezer. Work quickly. Do not allow
the vials to warm.
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HYCELL CHO MEDIA PREPARATION PROTOCOL (adapted from Thermo
Fisher-Scientific)
Purpose. To make sterile media for CHO cell growth and maintenance.
Materials.
 HyCell CHO
 Pluronic F68
 Sodium Bicarbonate
 L-glutamine
 1 L PETG sterile bottle
 Filter
Procedure. Use the following table to calculate the amounts needed for the
desired volume. Example below is for 1 L and 10 L.

Table D-1: HyCell CHO media prep calculation chart
Volume =

Preparation
Volume=

1.00 L
Conc.
Unit

10.00 L
Conc.
Unit

HyCell CHO

25.40 G

254.00 g

Pluronic F68

1.00 G

10.00 g

SODIUM BICARBONATE

2.20 G

22.00 g

L-Glutamine (USP Tested)

0.88 G

8.78 g

Component
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1. Weigh out the correction g unit for the desired volume of media.
2. Add distilled H₂O about 1 L less than the total desired volume.
3. Mix powders until dissolved with a stir bar. Once completely in
solution stop stirring and add remaining volume to bring solution up to
final desired volume.
4. Measure pH of the solution using a pH meter. pH should be between
7.0-7.2.
5. Adjust the pH as necessary.
6. Sterile filter mixed media into sterile 1L PETG bottles.
7. Store media for up to 1 yr at 4-8 °C.
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Vi-CELL ANALYZER (adapted from Thermo Fisher-Scientific)

Purpose. The purpose of this document is to describe the correct operation of the ViCELL Cell Viability Analyzer.
Materials.
Trypan Blue (sigma)
Coulter clenz (cleaning agent)
70% Isopropanol (disinfectant)
Diluent (buffer solution)
Procedure.
1. Under files choose configuration. Choose the software tab. Under paths, the
data file should read: C:\(Your Name). Choose OK. Place sample cup in next
available carousel position. Log in sample by clicking on the log in sample
button. Select sample cup position on the carousel (if applicable).
2. Enter sample ID.
3. Choose the cell type.
4. Click OK.
5. Press start queue to begin analysis.
NOTE. Vi-CELL will automatically clean itself with each sample. Refer to
product manual for all maintenance procedures such as reagent pack replacement,
etc.
References. Beckman Coulter Vi-CELL Cell Viability Analyzer Manual #PN
383082A. Accessible under HELP button on Vi-CELL computer software.
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tPA ELISA PROTOCOL (adapted from Thermo Fisher-Scientific and Enzyme Research
Laboratories)
Materials.
Tissue Plasminogen Activator ELISA kit: from Enzyme Research Laboratories
(South Bend, USA)- TPA-EIA
Coating buffer: Sigma-Aldrich C-3041
Wash buffer: Sigma-Aldrich T9039-10PAK
Blocking buffer: Sigma-Aldrich T6789-10PAK
Sample diluent: blocking buffer + Tween-20, 0.05% vol vol-1
Ultra TMB- Thermo Fisher-Scientific catalog #34028
Stopping solution- 2.5 M H2SO4
96-well polystyrene 4-HBX clear flat bottom plate
Procedure.
1. Coating of plates. Coat the 96-well plates with the capture antibody (provided
from the TPA-EIA kit from Enzyme Research Laboratories). Dilute the antibody
1:100 in a 0.05M Carbonate-Bicarbonate buffer (Sigma-Aldrich). This buffer
helps stabilize the proteins by maintaining their three-dimensional structure which
in turn helps with greater binding activity. Add 100 µL of diluted antibody to
each well in the plate. Incubate for 2 h at room temperature or overnight at 2-8°C.
2. Blocking. After incubation with the capture antibody, the plate is treated with
blocking buffer. The blocking buffer used is Tris buffered saline with BSA
(Sigma). This will block unoccupied areas of the wells and prevent nonspecific
binding which will reduce the background signal. To do this, empty the contents
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of the plate and add 150 µL to each well of blocking buffer (Tris buffered Saline
with BSA) and incubate for 60 min at room temperature. After incubation, wash
the plate 3 times with wash buffer, Tris buffered saline plus Tween-20, 0.05%
(Sigma-Aldrich) (100-150 µL per well with each washing).
3. During the incubation with blocking buffer, tPA reference standards and samples
are prepared.
a. Standards. Dilute the tPA standards in sample diluent, Tris buffered
saline with BSA plus Tween-20 0.05%. Use a six reference standard with
final tPA concentrations of 50, 25, 12.5, 6.25, 3.13 and 1.56 ng/mL. Add
100 µL of standard to each assigned well. Standards must be run in
duplicate.
b. Samples. For the CHO 1-15 cell line grown in 100 mL shaker flask up to50 L S.U.B. the samples should be diluted 1:2,000. Accomplish the
1:2,000 dilution with 2 steps.
i. 1. Perform a 1:100 dilution with 10 µL of sample into 990 µL of
sample diluent.
ii. 2. Perform a 1:20 dilution with the number 1 step (1:100 sample)
50 µL into 950 µL of sample diluent.
Add 100 µL of sample are added to each well. Samples should be run in
duplicate. Samples can be run in triplicate if needed. The coated antibody
will capture the tPA present in the sample. After samples are added,
incubate the plate at room temperature for 90 min. After incubation, wash
the plate 3 times with wash buffer. Be careful not to cross contaminate the
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wells after samples have been incubated. Use Nunc sealing tapes to
produce better results.
4. Detecting. Dilute the detecting antibody 1:100 in sample diluent, Tris buffered
saline with BSA plus Tween-20, 0.05%. The detecting antibody binds to the
captured tPA. Add 100 µL of diluted detecting antibody to each well and
incubate at room temperature for 90 min. After incubation wash the plate 3 times
with wash buffer.
5. Ultra TMB. The Ultra TMB detects peroxidase activity from the detecting
antibody, changing to a blue color. Add 100 µL per well of Ultra TMB. The
reaction is very quick, it is best to keep the ultra TMB cold until ready for use.
Leave on the substrate on for 1 -2 min, then add 50 µL of 2.5 M H₂SO₄ to each
well. The acid will change the color from blue to yellow and slow down the
reaction. Immediately read the wavelength at 450nm.
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2L BIOREACTOR INSTRUCTION PROTOCOL (adapted from Thermo Fisher
Scientific)
Purpose. The purpose of this manual is to explain the operations associated with
maintaining the Applikon 2L bioreactor in the BioProcessing Demonstration and
Training lab. T h e first priority of any bioreactor process is to provide a sterile
environment for cell growth. Sterilization is an important step in preparing the
bioreactor prior to inoculation, and that sterile environment must be maintained
throughout the entire process. Maintaining a sterile environment consists of two steps:
1) cleaning and sterilization of all equipment used in the process; and 2) the sterile
transfer of media and cells in and out of the system. With the use of good lab
techniques the risk of contamination can be reduced.
A. Cleaning of glass vessel, tubing, and head plate/components.
Objective. This procedure outlines the disassembly, cleaning, pre-sterilization, and
rinsing of the bioreactor vessel, headplate, and all ports and probes.
Materials.
Tergazyme by Alconox
Sponge, pipe cleaners, toothbrush, toothpaste, large brush
Appropriate tools to disassemble the reactor
Sodium Hypochlorite (bleach)
Procedure.
1. Remove the DO probe from the headplate. Clean with a sponge or soft
toothbrush and detergent. Rinse first with hot tap water, and then with a final
rinse in DI water. Store probe in an upright position with the tip of the probe in
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DO electrode storage solution or PBS.
2. Remove the pH probe from the headplate. Clean with a sponge or soft
toothbrush and detergent. Rinse with hot tap water. Store in an upright position
in pH electrode storage solution
3. Remove all tubing from the headplate. Do not reuse tubing and filters, with the
exception of the exhaust filter set. (That filter can be re-autoclaved between 612 times depending on the application).
4. Remove the headplate from the glass vessel (make sure all cables, etc. are
disconnected before headplate is removed). Bleach cells and dump them prior
to cleaning the vessel. Take off all removable parts on the headplate to ensure
thorough cleaning.
5. All parts (including the vessel) can be cleaned with a sponge or brush and the
hot water detergent mix (hot water and Tergazyme). Clean the inside of all ports
with a pipe cleaner. Soak the micro sparger in hot water detergent mix, then
bleach to make sure that all the holes are free of debris.
6. Allow all parts to air dry on a disinfected surface (or paper towels).
B. Assembly of apparatus.
Objective. This procedure outlines the preparation of the tubing, headplate assembly,
insertion of the probes, and connecting the bioreactor to the Applikon console.
Materials.
Silicone tubing (3/16 x 3/8 x 3/32, for harvest, air filter, and condenser lines)
Silicone tubing (1/8 x 1/4 x 1/16, for ends of harvest, feed, and condenser lines)
Tubing accessories
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1/8" to 3/16" connectors
1/8" female lure lock
Male lure lock cover
Snapper clamps
Cable ties & cable tie fastener
Whatman Poyvent 16 filters (50mm)
1-1.5L of PBS
DO electrolyte
Glycerol
Whatman Polyvent 500 exhaust filter, or equivalent
Procedure.
1. Once the headplate has been cleaned and dried, put 1-1.5L of the DPBS in
the bioreactor.
2. Place the rubber-sealing ring in the headplate.
3. Make sure the impeller is firmly attached to the headplate and that all
removable parts have been put back onto the reactor, and place the headplate
on the glass vessel.
4. Tighten the nuts that go on top of headplate carefully, always tightening the
clamps across from each other at the same time.
5. The tubing should be prepared similar to the existing pattern and attached to the
following locations (figure 1)
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Figure G-1: Applikon headplate configuration


Tubes for harvesting, and sampling
o 1 long tubing length for harvest port
o 3'-4' of 3/8"x3/16" silicone tubing
o 6" of 1/8"x1/4" silicone tubing
o 1/8" to 3/16" connector
o 1 snapper clamp
o 3 cable ties (one at each connector end)
o Lure lock sample piece for sample port (skinny port that goes partway
down the vessel)



Triport Feeding lines
o 2-3' of l/8"xl/4" silicone tubing for each triport spot
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o Snapper clamp
o 1/8" end plug
o Cable ties


Condenser vent assembly
o 3'-4' of 3/8"x3/16" silicone tubing in 3 pieces
o 1/4" Y connector
o Whatman Polyvent 500 and snapper clamp for one end
o 6" of 1/8"xl/4" silicone tubing, 118" end plug, and snapper clamp for
other end
o 7 cable ties (one at each connector end)



Shorter gas addition filters
o 3"-4" of 3/8"x3/16" silicone tubing for each line
o Whatman Polyvent 16 Filter for each line
o Snapper clamp for sparge line
o Cable tie for each line

6. Use two cable ties to secure the tubing to the headplate.
7. Unscrew the end of the DO probe and inspect the mesh at the tip. Make sure
the mesh membrane is not damaged. Refill the cap with DO electrolyte and
screw it back in place. Insert the DO probe into its port. Adjust the probe so
that it does not come in contact with the impeller, and tighten.
C. DO and pH Calibration and Autoclaving the Bioreactor:
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Objective. This procedure outlines the calibration of the DO and pH probes, as well as
the sterilization of the bioreactor using the autoclave located in either QC or
production.
Materials.
pH 7.00 and pH 4.01 calibration buffers.
Large autoclave bag
Calibration of the pH Probe.
1. Turn on the ADI 1010 Bio Controller and make sure all the control loops are
switched off. And attach the pH probe to its cable.
2. Enable the calibration screen. Press the pH key. A list of options appears. Press
the CALIB key. The calibration menu appears. Turn the dial to highlight
CALIBRATION then press the CALIB key to continue.
3. Rinse the pH probe with distilled water to remove all traces of the storage
solution.
4. Immerse the pH probe into the pH 7.00 buffer solution and momentarily stir
with the probe to ensure proper contact. Allow a minimum of 30 seconds for
the electrode to thermally equilibrate with the buffer solution before taking a
pH reading. You must let the probe totally equilibrate before calibrating, it may
take up to 15 minutes, do not speed the calibration along. The pH reading
should be 7.00 pH± 0.33 pH at room temperature, 25°C
5. First the buffer temperature must be entered. Use the dial in order to generate
the numeric buffer temperature value. Once temperature is entered press the
CALIB key to continue.
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6. Now the pH of the first buffer is asked for, use the dial to generate this value
and press CALIB key to continue.
7. Rinse the pH probe with distilled water.
8. Immerse the pH probe in pH 4.01 buffer solution and stir with probe to ensure
proper contact. Allow a minimum of 30 seconds for proper electrode/solution
equilibrium before taking a pH reading, again do not speed this process along,
make sure that the probe is equilibrated before calibrating.
9. Press the CALIB key to proceed with the dual point calibration and use the dial
to generate the correct value of this buffer and press the CALIB key. This will
return the calibration data. Press the SETP key to return to the main screen.
10. Rinse the pH probe with distilled water.
11. Insert the pH probe into its port and assure that it will not come in contact with
the impeller, and tighten
Autoclaving the Bioreactor.
1. The bioreactor should already contain 1.5L of DPBS, which is necessary when
autoclaving.
2. All of the clamps leading to vents and filters should be closed, except the
clamps for the condenser vent and the overlay filter should be left open.
These are left open because they are not submersed in the DPBS and it is
necessary to leave an outlet open so that pressure does not build up in the
reactor.
3. The top of the bioreactor with all tubing, filters and vents should be covered with
a large autoclave bag. Note: make sure the DO and pH probes are both covered
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with their appropriate caps and screwed tightly in the bioreactor.
4. Make sure that the bioreactor is completely disconnected from the Bio
Controller, and Place the bioreactor in the autoclave. Autoclave on liquid cycle
(slow exhaust) for 30 minutes.
5. When the autoclave run is over, allow the reactor to cool enough for transport,
and then return it to the lab.
6. Allow the vessel to cool before reattaching all of the probes, inlet gas lines,
heat jacket, temperature probe, and water hoses.
7. Hook up the vessel, all probes, and water hoses to the consol. Add
approximately2-3ml of glycerol to the temperature well before putting the
temperature probe in the well.
8. Turn on the machine and allow the DO probe to polarize for at least 6 hours
before calibrating. Attach heat jacket and turn on the temperature control to
allow the DO probe to polarize at the working temperature. Also, turn on the
agitation to allow better heat exchange in the vessel, and turn on the air to the
sparger to allow the vessel to saturate with air.
9. To turn on the air, use a screwdriver to turn the air valve on the console to
sparge, and make sure that the sparge line is attached to the sparge filter.
10. Make sure the DO control loop is turned off. Press MENU key and use the dial
to select the MANUAL CONTROL option. Press MENU again to continue.
11. Use the dial to select the AIR VALVE option and press START/STOP key to
get to the ON/OFF column. Use the dial to toggle between the two options and
press START/STOP again to confirm action (that valve is on). Press SETP key
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to return to main screen.
Calibration of the DO Probe.
1. Make sure that the temperature control is turned on (press TEMP key, then
START/STOP key) and that the liquid in the reactor has equilibrated to desired
run temperature (generally 37°C). If set point of temperature is not at desired
set point (i.e. 37°C) change it by pressing TEMP key, then SETP key, the using
dial to change the set point value, it will then automatically change it after a
minute to the desired value.
2. Make sure the agitation is at least 100-150 rpm. And that air is being pumped into
system; see above instructions to turn it on.
3. Allow system to stabilize for approximately 10 minutes (this may take up to 30
minutes).
4. Start the calibration by pressing the d02 key, followed by the CALIB key.
Press the CALIB key again to continue.
5. Use the dial to generate the value 100 and press the CALIB key to continue.
6. The stabilized value is used to calculate the slope of the electrode, which is
shown. Press the SETP key to finalize the calibration.
7. The reactor is now ready for seed.
D. Removal of DPBS and Addition of Media and Seeding Bioreactor
Objective. Use a sterile technique for removing the DPBS and the addition of the desired
media prior to a bioreactor run.
Materials.
Peristalstic pump
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Desired media
Transfer union
Procedure.
1. Disconnect all probes, gas lines and water lines and transfer the 2 L bioreactor to
a laminar flow hood. In the laminar flow hood, using sterile technique, Pump out
the DPBS with the peristaltic pump.
2. When the DPBS has been removed, turn off the pump and clamp off the tubing to
maintain the sterile environment.
3. Prior to inoculation, warm media in 37°C incubator then in the laminar flow hood
connect one of the feed lines to the transfer union of the media- containing liter
bottle. (Use a fresh transfer union for each bottle in order to add the media to the
bioreactor.)
4. Under a hood, extract at least 1 mL of cell media from the well-mixed fernbach
and put into a cell counter vial.
5. Use the Vi-CELL cell counter to determine how many viable cells there are per
mL.
6. Use the following equation to calculate how much of the cell media needs to be
transferred to the bioreactor in order to achieve a cell concentration of
approximately 250,000 cells/mL.
a. You can calculate your split ratio using the formula: (V1)(C1)=(V2)(C2).
Solve for V1
V1= the volume of spent media needed to seed bioreactor
C1= the density of cells/media in flask

107
V2=the desired final volume of media in bioreactor (2 L)
C2=the seeding density of media in bioreactor (250,000 cells/mL)
7. Once you have determined how many mL of the cell media needs to be used to
inoculate the bioreactor, transfer that amount from the fernbach flask to the 1 L
PETG bottle under the hood.
8. While still under the hood, open the autoclave bag containing the sterile transfer
union. Careful not to touch the tubing below the rubber stopper with anything,
insert the transfer union into the PETG bottle with cell/media mixture and the
media PETG bottles.
9. Using the laminar flow hood with aseptic technique, connect the transfer union to
one of the addition ports of the bioreactor.
10. Place the tubing in the pump and make sure that the pump is set to turn in the
appropriate direction to feed the cells into the bioreactor.
11. Using aseptic technique, disconnect the transfer bottle from the bioreactor,
keeping the tubing sterile and the connections closed off.
12. Use the pump to add the media. Disconnect the media vessel and connect to the
media/cell mixture. Pump the media/cell mixture into the bioreactor. Disconnect
the vessel with sterile technique.
13. Transfer the bioreactor out of the laminar flow hood and back onto the bench top.
Re-attach all the probes, cables and water lines. Turn on agitation at 300rpm and
the temperature control loop. Allow the cell/media mixture to reach the desired
temperature. Once at 37°C the DO, and pH, control loops must be turned on. Do
this by pressing the desired parameter key (temp, DO, etc.) then pressing
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START/STOP key.
E. Adding Base
Background. To keep pH at the set level, it may be necessary to add base. Base will keep
the culture from going below the desired pH by adding in small increments of the base
into the media. Carbon Dioxide, if it is turned on, will keep the pH from rising above the
desired set point.
Objective. Maintain the pH parameter by adding a base that will keep the pH from
drifting downward.
Procedure.
1. Make 10-20% (w/v) Sodium Carbonate solution or equivalent, sterile filter, and
add a transfer union under a sterile environment.
2. Connect the base to the sterile tubing on the addition port under the laminar flow
hood.
3. Place the base addition line into the base pump on the console, making sure that
the tubing is added in the correct direction. (The pump move in a clockwise
motion), and make sure the clamps are opened between the base vessel and the
reactor.
4. The base will now automatically be pumped in, if the pH control loop is turned
on.
F. Connecting of Vessel to Input Gases
Background.
The Applikon allows the input of gas through overlay or sparge. The only gases
hooked up to the Applikon reactors are oxygen, air and CO₂ , To control DO and pH
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with these gases, the control loop has to be turned on, and the valves switched on to
the desired pathway, sparge or overlay. The pH control also automatically turns on the
base pump is the pH is too low, so this can be utilized to help maintain the ideal pH.
Procedure.
1. Attach the tubing from the direct sparge line to the filter for the direct sparge on
the bioreactor. Open the clamp leading to the filter.
2. Attach the tubing from the overlay sparge line to the filter for the overlay
sparge on the bioreactor. Open the clamp leading to the filter.
3. Once the Applikon console has been set to turn on the gas, the regulators (flow
meters) for the oxygen, air and CO₂ should be adjusted, they usually are run
around 300 mL/min at the start of the run.
G. Taking Samples
Background. In order to monitor the progress of the run it is necessary to take a
representative sample from the bioreactor on a regular basis. Under normal conditions,
the appropriate sample time is once a day. In order to maintain consistency, it is
important to take samples at the same time each day
Objective. During the course of a run the most probable cause of contamination is
from sampling. For this reason the objective in sampling is to get a representative
sample from the bioreactor without compromising the sterile environment. By
taking extra caution while sampling, and being consistent in the sampling method the
possibility for contamination from sampling can be drastically reduced.
Materials.
15mL sample tube with lid
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Sample tube rack
2 small centrifuge tubes
10mL lure-lock syringe
Isopropanol
Bleach
Cell counter and counter vial
Centrifuge (microfuge)
Procedure.
1. Apply copious amounts of isopropanol to the lure-lock sample port.
2. Wearing gloves remove the lure-lock cap and apply more isopropanol to the cap
and male lure-lock end. (Make sure that the sample port clamp is closed before
removing the cap.)
3. Attach the syringe to the sample port, release the sample port clamp, and fill the
syringe with solution from the bioreactor. Make sure you keep positive pressure
on the syringe, so there is no backflow into the reactor. Clamping the sample port
before taking the syringe off will also insure no backflow.
4. Discard at least 10mL of solution from the bioreactor into the discard basin to
insure that the final sample is coming from the well-mixed bioreactor, Add a
small amount of bleach to the unwanted solution, and dump down the drain with
plenty of water.
5. Pull approximately 10mL of sample from the bioreactor. Using the syringe, fill
the two centrifuge tubes with equal amounts of solution, and then put the
remaining volume of the syringe in the 15mL sample tube.
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6. Apply more isopropanol to the sample port end and the cap, and then replace the
cap. Make sure the clamp to the sample port is closed.
7. Count 1mL of the sample with the Vi-CELL. Centrifuge the remaining sample in
the 15mL tube for 4 min at 1,000rpm.
8. Take 2 1mL samples of the supernatant and store in small centrifuge tubes clearly
labeled in the freezer until needed for further use
9. Record the data collected in your lab book.
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APPENDIX H
50 L S.U.B. PROTOCOLS
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50 L S.U.B. PROTOCOLS (adapted from Thermo Fisher Scientific)

A. Loading BPC into 50 L S.U.B.
Background. Each outer support container is designed for a specific Single-Use
Bioreactor (S.U.B.) BioProcessing Container bag (BPC). Confirm the correct volume
BPC is being used for the corresponding volume outer support container. The following
section outlines the installation and setup of the S.U.B. BPC.
Procedure.
1. Remove irradiated bioreactor BPC from protective double polybags.
2. Load BPC from the top into the outer support container.
3. Orient BPC with bearing port up and toward motor drive with Kleenpak
connector probe ports facing bottom access cut-out.
4. Place the bearing port into bearing port receiver, close door and close clamp.
5. Route the side and bottom ports through the side access panel and slot in tank
bottom.
6. Direct the sparge, bottom drain and sampling lines through outer support
container access windows. NOTE: The 500 L systems have a hatch covering the
access window for the bottom sparger.
7. Connect incoming gas feed lines to both the overlay filter and the direct sparge
filter.
8. Inflate BPC with air (inflation time approximately 20 min) through overlay filter,
but do not exceed 0.5 psi (0.34 bar) internal BPC pressure. As BPC inflates,
ensure it is properly oriented in the support container (port alignment, drain,
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sparge, etc.).
9. As the bag begins to fill with air, manipulate the bag to align the sparge line in the
base.
10. Use the four bottom cut-outs located at the base of the support container as a
reference to align hanging tabs on the BPC.
11. Attach platform stretch hooks to each of the four bottom corners of the BPC
position bottom-side drain, pulling out/downward to position port towards bottom
edge of tank.
12. Align row of Kleenpak connector probe ports within access window.
NOTE: Verify all port clamps are closed and located as close as possible to the
body of the S.U.B. BPC.
13. Remove the latch pin from the safety cover over the mixing assembly and open
the cover. Unscrew the threaded cap covering the hollow pass-through of the
motor.
14. Assemble the upper and lower sections of the drive shaft by joining the segments
and with a counterclockwise motion, hand-tighten the two sections together.
15. Remove latch pin.
16. Locate one wrench on the flat area in the lower drive shaft section, another
wrench on the upper section and tighten the connection using a counterclockwise
rotation. The shafts are reverse threaded to avoid loosening during operation.
Caution: Do not over tighten; a "snug" fit is sufficient.
17. Once the sections are secure, return the wrenches to the tool holder.
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B. Drive Shaft Insertion
Procedure.
1. Use two hands to load drive shaft through top of mixing assembly; a slight back
and forth twisting motion will aid in insertion.
2. When approximately 2" of shaft remains, twist slightly to engage impeller.
3. When approximately 1" of shaft remains, twist slightly to engage bearing
assembly.
4. When approximately 0.25" of shaft remains, twist to align motor drive keyway
with one of the four outer slots on the drive shaft head.
5. Directly couple drive shaft to motor drive.
6. Place threaded cap on hollow pass-through and hand tighten clockwise.
7. Tighten cap by placing spanner wrench on hollow pass through and tighten cap
using supplied torque wrench.
8. Close safety access cover and insert latch pin.
9. The air supply to the overlay can be turned off once the drive shaft has been
inserted.
10. Connect heater to controller and verify it is plugged into an appropriate 120 or
240 VAC outlet, then connect the power cord to the controller.
11. Secure exhaust vent filter on side-mounted holder
C. Filling S.U.B. with Media
Background. Order media from the warehouse to be transferred to the USU lab. Media
may come in bags, barrels, large space craft containers or other modes of packaging. The
media packaged in these applications is sterile and only needs to be transferred to the
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bioreactor for use.
Procedure.
1. Select desired line set from top of S.U.B. BPC for fluid introduction.
2. Make aseptic connection (quick connect) and begin liquid fill. This is done by
using a laminar flow hood to make the connections to ensure sterility.
3. Once approximately 10-20% of volume has been added, verify the position of
the BPC in the outer support container, particularly the sparger and the drain
line. Adjust positioning if necessary for proper fit.
4. It is recommended that the top corners of the BPC be pulled upward to reduce
wrinkles during filling. NOTE: The BPC must be pulled at the top corners as
the bag will generally form wrinkles during liquid fill. If the film is not pulled
from the top to remove wrinkles, film tensioning below the bearing port will
result.
5. The stretch hooks can be removed from bottom corners of the S.U.B. BPC
when fluid volume reaches 30% volume. This will eliminate any interference
with the load cell readings.
6. Fill to desired liquid volume; 50%-100% of rated volume is recommended.
7. The unit is also ready to be set to warm media to 37° C using the electric
blanket or the TCU water bath system.
8. Once all the media is transferred to the bioreactor by sterile methods, and is
warmed to 37° C, the unit is ready to start the DO calibration.
9. The propeller that operates the agitation of the S.U.B. bioreactor can also be
initiated to desired speed.
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D. Agitation of S.U.B. Bioreactor
Procedure.
1. Once the media has reached half volume of the S.U.B., the agitation control can
be turned on via the motor ON/OFF switch.
2. Using the arrow keys, adjust the set point speed to the desired level. Adjust
desired agitation rate based on cell type and liquid volume. (For CHO 1-15 in 50
L S.U.B. use 169 RPM)
3. Allow speed to stabilize, and make fine adjustments if necessary.
Seeding a Bioreactor
Materials.
PBS
Media
Silicone Tubing
HyClone BPC
Air Filters
Bioreactor
Peristaltic Pump
Procedure.
1. Once the S.U.B. is operating at the targeted steady equilibrated state and has
achieved temperature, the S.U.B. is ready for inoculation. Do not seed bioreactor
until it has been plumbed, autoclaved, and calibrated.
2. Count and check viability of cells to be used to seed the bioreactor study.
Calculate how many mL of cells you will need to seed the study. Seeding density
is 250,000 cells/mL.
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3. Take the seeding density and multiply it by the total volume; this is the total
number of cells needed. Divide the total number of cells by the viable cell count.
The result is the volume of cells you need to seed this study.
4. Connect the inoculum addition line set to the seed culture vessel (2 L) bioreactor
(equipped with the proper connectors/tubing) to the inoculum line on the 50 L
S.U.B. This is done with the aseptic luer lock.
5.

Use a peristaltic pump to pump the desired volume of seed cells into the S.U.B.
NOTE: For shear sensitive cultures, cells can be introduced by manipulating the
addition port to direct the inoculum down the interior wall of the BPC and into the
bulk fluid, reducing the shear on the cells.

6. Once seeded, set the controls (air, pH, and DO) for the study.
7. If necessary, add additional media as described in section to achieve desired final
volume.
8. Take an initial sample to verify actual seeding density.
9. Check that the pH probe is reading correctly. If pH is off, re-adjust it by adjusting
the zero on the bioreactor to match the reading of the external pH reading.
E. Sampling a Bioreactor
Procedure.
1. Once the bioreactor has been seeded, samples can be taken sterilely through the
sample port.
2. Ensure sample port clamp is closed, then unscrew cap.
3. Attach sterile syringe (10-20 mL size) to end of sample port.
4. Draw out cells, keeping positive pressure towards the syringe (before unclamping
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sample port, make certain to maintain positive pressure on the port).
5. Fill the syringe 2-4 times, closing clamp and dumping cells each time.
6. The final time cells are drawn out, put into 15 mL centrifuge tube to save.
7. Alcohol the opening and cap of sample port before replacing the cap.
8. Collect a 1 mL sample and count the cells with the Vi-CELL to determine
viability and density.
9. Centrifuge the rest of the sample at 1,000 RPM for 4 min. Save a 1 mL sample of
the supernatant for ELISA analysis and freeze at -20°C until needed for use.
F. Sterilization of Bioreactor Waste
Background. Chlorine is a widely accepted liquid sterilizing agent. Various chemical
forms are available and acceptable for use as a sterilant. A minimum concentration of 500
ppm halogen is necessary for effective sterilization, although 3,000 ppm is recommended
for spent media.
Warning/Safety Precaution. Do not mix hypochlorite compounds with ammonia or
strong acids under any circumstances; chlorine gas, nitrogen trichloride, and / or
hydrazine generation may result, which can be deadly. All chlorine compounds are
considered highly corrosive, so always wear appropriate protective gear and avoid
corrosion of equipment.
Procedure.
1. Wear appropriate personal protective equipment when performing any
sanitization process.
2. Calculate amount of chlorine compound required to bring the liquid to 3000 ppm
final concentration.
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3. Add required amount of chlorine compound to liquid waste. Mix thoroughly, and
allow to react for at least 30 min.
4. Flush sterilized liquid down drain with running tap water.

Table H-1: Bleach reference chart
Compound
Sodium
hypochlorite
Calcium hypochlorite
Calcium hypochlorite, bleaching
powder
Sodium
dichloroisocyanurate
Sodium tosylchloramide

Available
Chlorine

g/L
500ppm

g/L
3000ppm

5.25%

9.5

57.1

70-72%

0.7

4.2

35%

1.4

8.6

60%

0.8

5

25%

2
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